


527 Rec'd PCT/11.11.00 06 NOV 2000

FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 1430-256
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/674716 (To Be Assigned)
INTERNATIONAL APPLICATION NO. PCT/GB99/01434	INTERNATIONAL FILING DATE 7 May 1999	PRIORITY DATE CLAIMED 9 May 1998
TITLE OF INVENTION ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC USES		
APPLICANT(S) FOR DO/EO/US BONNEFOY et al. Jean-Yves Marcel Paul.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. To 16. Below concern document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information. PTO-1449/ International Search Report		

529 Rec'd PCT/PTC 06 NOV 2000

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/07/16		INTERNATIONAL APPLICATION NO. PCT/GB99/01434		ATTORNEY'S DOCKET NUMBER 1430-256	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)): -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$710.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$690.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	19	-20 = 0	X \$18.00	\$	0.00
Independent Claims	8	-3 = 5	X \$80.00		400.00
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$270.00	\$	0.00
TOTAL OF ABOVE CALCULATIONS =				\$	1390.00
Reduction by ½ for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 C.F.R. 1.9, 1.27, 1.28).					0.00
SUBTOTAL =				\$	1390.00
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					0.00
TOTAL NATIONAL FEE =				\$	1390.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				+	\$ 0.00
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)					0.00
TOTAL FEES ENCLOSED =				\$	1390.00
				Amount to be:	
				refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1390.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application. NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 th Floor Arlington, Virginia 22201 Telephone: (703) 816-4000					
				 SIGNATURE	
				Arthur R. Crawford NAME	
				25,327 REGISTRATION NUMBER	
				November 6, 2000 Date	

09/674716
529 Rec'd PCT/PTC 06 NOV 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BONNEFOY et al.

Atty. Ref.: 1430-256

Serial No. (To Be Assigned)

Group:

National Phase of PCT/GB99/01434

Filed: November 6, 2000

Examiner:

For: **ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND
THEIR THERAPEUTIC USES**

* * * * *

November 6, 2000

Assistant Commissioner for Patents
Washington, DC 20231
Sir:

PRELIMINARY AMENDMENT

Prior to calculation of the filing fee and in order to place the above identified application in better condition for examination, please amend the claims as follows:

IN THE CLAIMS

Claim 4, line 1, change "any of the preceding claims" to --claim 1--.
Claim 6, line 1, change "any of the preceding claims" to --claim 1--.
Claim 7, line 1, change "any of the preceding claims" to --claim 1--.
Claim 10, line 1, change "any of the preceding claims" to --claim 1--.
Claim 12, line 1, change "any of claims 1-10" to --claim 1--.
Claim 14, line 2, change "any of claims 1-10" to --claim 1--.
Claim 18, lines 1-2, change "any of the claims 1-10" to --claim 1--.
Claim 19, lines 1-2, change "any of claims 1-10" to --claim 1--.

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHIE P.C.

By:


Arthur R. Crawford

Reg. No. 25,327

ARC:ms

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



674 674 674 674 674 674 674 674 674 674

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BONNEFOY et al.

Atty. Ref.: 1430-256

Appln. No. 09/674,716

Group Art Unit: Not Known

Filed: January 22, 2001

Examiner: Not Known

FOR: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THERAPEUTIC USES

* * *

SUBMISSION OF CORRECTED SEQUENCE LISTING

November 21, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Notification of Defective Response mailed October 22, 2001, entry of the following amendments and remarks is respectfully requested.

IN THE SPECIFICATION

Kindly enter the following paragraphs.

Page 1 after the title, add the following:

This is a national stage application of PCT/GB99/01434, filed on May 7, 1999 under 35 U.S.C. 371, now abandoned.

Page 19, line 12, replace the paragraph with the following heading:

BRIEF DESCRIPTION OF THE DRAWINGS

IN THE ABSTRACT

Kindly enter the attached abstract of the disclosure.

IN THE SEQUENCE LISTING

Kindly enter the attached substitute paper and computer readable forms of the Sequence Listing in lieu of the Sequence Listing submitted on June 25, 2001.

578380

REMARKS

Claims 1-19 are pending. No extension of time is required because this reply is being made within one month from the mailing date of the Notification.

Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the requirement to comply with the Sequence Rules 37 CFR § 1.821 et seq. The attached substitute paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. Prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.


No new matter is added by the amendments. In particular, a priority claims after the title, a section heading for the brief description of the drawings, and the original abstract on a separate sheet are added. Furthermore, the addition of SEQ ID NOS:13 and 14 is supported by page 3, line 31, and page 8, line 18, of the specification.

Applicants earnestly solicit an early examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

APPENDIX
MARKED-UP VERSION TO SHOW CHANGES

IN THE SPECIFICATION

The following new paragraph is added on page 1 after the title:

This is a national stage application of PCT/GB99/01434, filed on May 7, 1999
under 35 U.S.C. 371, now abandoned.

The second paragraph on page 19, line 12, is amended as follows:

BRIEF DESCRIPTION OF THE DRAWINGS [Figures]

IN THE ABSTRACT

The abstract is attached.

IN THE SEQUENCE LISTING

The substitute paper and computer readable copies of the Sequence Listing are attached.

ABSTRACT OF THE DISCLOSURE

The invention relates to antibodies which bind to the CD23 (FC ϵ RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC ϵ RII) type II molecule characterized by an affinity constant equal to or greater than 1×10^9 Ka Mol $^{-1}$, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.



13 Rec'd PCT/PTO 08 JUL 2002
09/674716

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BONNEFOY et al.

Appln. No. 09/674,716

Filed: January 22, 2001

Atty. Ref.: 1430-256

Group Art Unit: Not Known

Examiner: Not Known

FOR: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THERAPEUTIC USES

* * *

SUBMISSION OF CORRECTED SEQUENCE LISTING

July 8, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Notification of Defective Response mailed June 20, 2002, entry of the following amendments and remarks is respectfully requested.

IN THE SPECIFICATION

Kindly enter the following paragraphs.

Page 1 after the title, add the following:

This is a national stage application of PCT/GB99/01434, filed on May 7, 1999 under 35 U.S.C. 371, designating the United States and published in English.

Page 6, replace the third paragraph starting at line19 with the following:

The framework of the variable region of the antibody light chain is typically substantially homologous to the variable domain framework of the protein HSIKGVII (SEQ ID NO:54, EMBL data base: Klobeck, H.G., EMBL data library submitted 7th April, 1986). There is a frameshift in this sequence at position 452. To rectify the reading frame, a deletion of base 452(T) is made.

[illegible]

Kindly replace the Sequence Listing submitted on November 21, 2001 with the attached substitute paper and computer readable forms of the Sequence Listing.

REMARKS

Claims 1-19 are pending. No extension of time is required because this reply is being made within one month from the mailing date of the Notification.

Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the requirement to comply with the Sequence Rules 37 CFR § 1.821 et seq. The attached substitute paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. Another amino acid sequence has been added. Prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.


No new matter is added by the amendments. In particular, the priority claims has been corrected and a sequence identifier has been added.

Applicants earnestly solicit an early examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

APPENDIX
MARKED-UP VERSION TO SHOW CHANGES

IN THE SPECIFICATION

The specification is amended as follows.

Page 1, first paragraph starting on line 1:

This is a national stage application of PCT/GB99/01434, filed on May 7, 1999 under 35 U.S.C. 371, [now abandoned] designating the United States and published in English.

Page 6, third paragraph starting on line 19:

The framework of the variable region of the antibody light chain is typically substantially homologous to the variable domain framework of the protein H₅IGKVII (SEQ ID NO:54, EMBL data base: Klobeck, H.G., EMBL data library submitted 7th April, 1986). There is a frameshift in this sequence at position 452. To rectify the reading frame, a deletion of base 452(T) is made.

IN THE SEQUENCE LISTING

Substitute paper and computer readable copies of the Sequence Listing are attached.

ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC USES

The present invention relates to antibodies which bind to the CD23 (FC ϵ RII) type II molecule particularly altered antibodies, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and
5 their use in therapy.

CD23 (FCERII) is a type II molecule of the C-lectin family which also includes the lymphocyte homing receptor (MEL-14) and the endothelial leukocyte
10 adhesion molecule-1 (ELAM-1). It is a low affinity receptor for IgE. In humans a variety of haematopoietic cell types express CD23 on their surface, including follicular dendritic cells, B cells, T cells and macrophages. CD23 molecules are also found in soluble forms in biological fluids. Soluble CD23 (sCD23) molecules are formed by proteolytic cleavage of transmembrane receptors.
15 CD23 has pleiotropic activities including mediation of cell adhesion, regulation of IgE and histamine release, rescue of B cells from apoptosis and regulation of myeloid cell growth. These functional activities are mediated through the binding to specific ligands of cell-associated CD23, or sCD23, the latter acting in a cytokine-like manner (Conrad, D.H., Annu Rev Immunol 8, 623-645
20 1990); Delespesse, G., et al., Adv Immunol 49, 149-191 (1991); Bonnefoy, J.Y., et al., Curr Opin Immunol 5, 944-47 (1993).

Increased expression of CD23 has been observed in a number of inflammatory diseases. CD23 has been identified in synovial biopsies from
25 patients with chronic synovitis, and sCD23 can be measured at concentrations exceeding the normal range in the serum and synovial fluid of patients with rheumatoid arthritis (Bansal, A.S., Oliver, W., Marsh, M.N., Pumphrey, R.S., and Wilson, P.B., Immunology 79, 285-289 (1993); Hellen, E.A., Rowlands, D.C., Hansel, T.T., Kitas, G.D., and Crocker, J.J., Clin Pathol 44, 293-296
30 (1991); Chomarat, P., Brioloay, J., Banchereau, J., & Miossec, P., Arthritis Rheum 86, 234-242 (1993); Bansal, A., et al., Clin Exp Immunol 89, 452-455 (1992); Rezonzew, R., & Newkirk, M.N., Clin Immunol Immunopathol 71, 156-163 (1994). In addition, levels of serum sCD23 in rheumatoid arthritis patients are related to disease status and correlate with serum rheumatoid factor
35 (Bansal, A.S., et al., Clin Exp Rheumatol 12, 281-285 (1994). Pro-

inflammatory cytokines appear to be particularly important in rheumatoid arthritis, and a central role for TNF-a and IL-1b in the destruction of arthritic joints has been postulated (Brennan, F.M., Chantry, D., Jackson, A., Maini, R., & Feldman, M., Lancet 2, 244-247 (1989); Brennan, F.M., Maini, R.M., & Feldman M., Br J Rheumatol 31, 293-298 (1992).

Antibodies typically comprise two heavy chains linked together by disulphide bonds and two light chains. Each light chain is linked to a respective heavy chain by disulphide bonds. Each heavy chain has at one end a variable domain followed by a number of constant domains. Each light chain has a variable domain at one end and a constant domain at its other end. The light chain variable domain is aligned with the variable domain of the heavy chain. The light chain constant domain is aligned with the first constant domain of the heavy chain. The constant domains in the light and heavy chains are not involved directly in binding the antibody to antigen.

The variable domains of each pair of light and heavy chains form the antigen binding site. The domains on the light and heavy chains have the same general structure and each domain comprises a framework of four regions, whose sequences are relatively conserved, connected by three complementarity determining regions (CDRs). The four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs are held in close proximity by the framework regions and, with the CDRs from the other domain, contribute to the formation of the antigen binding site. CDRs and framework regions of antibodies may be determined by reference to Kabat et al ("Sequences of proteins of immunological interest" US Dept. of Health and Human Services, US Government Printing Office, 1987).

The preparation of altered antibodies which the variable region of a rodent antibody is combined with the constant region of a human antibody is now well established in the art (Oi and Morrison (1986) Biotechniques 4, 214-212). Humanised antibodies in which the CDRs are derived from a source different from that of the framework of the antibody's variable domains are disclosed in EP-A-0239400. The CDRs may be derived from a rodent or primate

monoclonal antibody. The framework of the variable domains, and the constant domains, of the antibody are usually derived from a human antibody. Such altered antibodies should not elicit as great an immune response when administered to a human compared to the immune response mounted by a human against a wholly foreign antibody such as one derived from a rodent.

Murine monoclonal antibodies have been raised against the CD23 receptor (FC ϵ RII) (PCT/EP/95/04109). However, such monoclonal antibodies are not ideal for human therapy as they are potentially immunogenic when injected into a human patient and may be lytic. Furthermore commercially available antibodies which bind to the CD23 receptor recognise distinct epitopes expressed on the CD23 receptor; epitope binding specificity can play a significant part in the efficacy of an antibody for a particular purpose. Moreover, selection of antibodies with high affinity for the target receptor can be therapeutically advantageous as the dose required will be lower than for a monoclonal with less affinity for the same receptor.

According to the present invention, there is provided an altered antibody which comprises sufficient of the amino acid sequence of each CDR shown below that the antibody is capable of binding to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells:

light chain

RSSKSLLY KDGKTYLN	CDRL1 (SEQ ID NO: 3)
LMSTRAS	CDRL2 (SEQ ID NO: 5)
QQLVEYPFT	CDRL3 (SEQ ID NO: 7)

heavy chain

GYWMS	CDRH1 (SEQ ID NO: 9)
EIRLKSDNYATHYAESVKG	CDRH2 (SEQ ID NO: 11)
FID	CDRH3 (SEQ ID NO: 13)

The present invention also relates to an antibody which binds to the same epitope as an antibody having the CDRs described above. Competitive inhibition assays are used for mapping of the epitopes on an antigen such as

the CD23 molecule. For example FACS competition analysis involves the use of cells expressing the molecule as a target, the test antibody is labelled with one fluorochrome and a second antibody known to bind to the same antigen is labelled with a second differently coloured fluorochrome. If both fluorochromes are present the antibodies do not competitively inhibit each other and are therefore deemed to recognise separate epitopes on the target molecule. Epitope mapping can also be undertaken using direct peptide library binding assays in which peptide sequences from a target antigen are expressed on pins and screened using flourochrome-labelled antibodies as before. In epitope mapping studies the antibody having the CDRs described above has been shown to define a novel epiotpe on the CD23 molecule. The invention therefore provides an antibody which competitively inhibits the binding of an antibody having the CDR sequences set out above to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells.

An antibody according to the invention is preferably altered, it may be a chimaeric antibody which comprises sufficient of the variable heavy and light chain sequences of the murine antibody C11 set out in Figures 1 and 2 (SEQ ID 1 and 2 and SEQ ID 46, 47, 50 and 51) such that it is capable of binding to the CD23 molecule, and a human constant region. The antibody may be a chimaeric antibody of the type described in WO 86/01533 which comprises an antigen binding region and a non-immunoglobulin region. The antigen binding region is an antibody light chain variable domain and/or heavy chain variable domain. Typically the chimaeric antibody comprises both light and heavy chain variable domains. The non-immunoglobulin region is fused to the C-terminus of the antigen binding region. The non-immunoglobulin region is typically a non-immunoglobulin protein and may be an enzyme region derived from a protein having known binding specificity, from a protein toxin or indeed from any protein expressed by a gene. The non-immunoglobulin region may be a carbohydrate region. The two regions of the chimaeric antibody may be connected via a cleavable linker sequence. The altered antibody may also be a bi-specific antibody.

The altered antibody may be a humanised antibody in which sufficient of one or more of the amino acid sequences of each CDR (and if necessary

framework residues), is present in human frameworks such that it is capable of binding to the CD23 molecule.

5 Suitably, the CDRs of an antibody according to the invention are the light chain CDRs L1 to L3 and the heavy chain CDRs H1 to H3 above. The amino acid sequences of these CDRs may be changed, however. The amino acid sequence of each CDR may be changed by amino acid substitutions, insertions and/or deletions.

Each CDR may therefore include one or two amino acid substitutions, 10 insertions and/or deletions. There may be up to three amino acid substitutions, insertions and/or deletions in light chain CDRL3 or heavy chain CDRH3. Up to four amino acid substitutions, insertions and/or deletions may be present in light chain CDRL1. Up to six amino acid substitutions, insertions and/or deletions may be present in heavy chain CDRH2. Preferably the 15 amino acid sequence of each CDR is substantially homologous to that of each CDR set out above.

Preferably the degree of sequence identity is at least 50% and more preferably it is at least 75%. Sequence identities of at least 90% or of at least 20 95% are most preferred.

It will nevertheless be appreciated by the skilled person that high degrees of sequence identity are not necessarily required since various amino acids may often be substituted for other amino acids which have similar properties 25 without substantially altering or adversely affecting certain properties of a protein. These are sometimes referred to as "conservative" amino acid changes. Thus the amino acids glycine, valine, leucine or isoleucine can often be substituted for one another. Other amino acids which can often be substituted for one another include: phenylalanine, tyrosine and tryptophan 30 (amino acids having aromatic side chains); lysine, arginine and histidine (amino acids having basic side chains); aspartate and glutamate (amino acids having acidic side chains); asparagine and glutamine (amino acids having amide side chains) and cysteine and methionine (amino acids having sulphur containing side chains). Thus the term "derivative" can also include a variant

of an amino acid sequence comprising one or more such "conservative" changes relative to said sequence.

5 The framework and the constant domains of the antibody are preferably human framework and human constant domains. Preferably the framework of the variable region of the antibody heavy chain is substantially homologous to the corresponding framework of the human protein KOL (Schmidt et al, Hoppe-Seyler's Z. Physiol. Chem., 364 713-747, 1983). Homology in respect of the framework is generally 80% or more with respect to KOL, for example 10 90% or more or 95% or more. Furthermore, the seventh residue of framework 4 in KOL is suitably Thr or Leu, preferably Leu. This residue is KOL residue 109 by Kabat et al, 1987. A number of amino acid substitutions, insertions and/or deletions may be present. For example, one or more of the residues at position 49,66,76,77 and 94 may be altered to the equivalent residue in the 15 murine antibody. Other candidate framework changes that may be made to restore binding include amino acid residues 27, 30, 48, 67, 71, 91 and 93. The amino acid numbering is according to Kabat *et al supra*.

20 The framework of the variable region of the antibody light chain is typically substantially homologous to the variable domain framework of the protein HSIGKVII (EMBL data base: Klobeck, H.G., EMBL data library submitted 7th April, 1986). There is a frameshift in this sequence at position 452. To rectify the reading frame, a deletion of base 452(T) is made.

25 Homology in respect of the framework is generally 80% or more with respect to the chosen sequence, for example 90% or more or 95% or more. A number of amino acid substitutions, insertions and/or deletions may be present, for example at amino acid residue 64 but also or instead at 71 according to the numbering of Kabat et al.

30

The invention also provides an antibody which comprises the variable heavy and light chain sequences set out in Figures 3 and 4 (SEQ IDS 17 and 18).

35 The antibody preferably has the structure of a natural antibody or a fragment thereof. The antibody may therefore comprise a complete antibody, a (Fab')₂

fragment, a Fab fragment, a light chain dimer or a heavy chain dimer. The antibody may be an IgG such as IgG1, IgG2, IgG3 or IgG4; or IgM, IgA, IgE or IgD or a modified variant thereof. The constant domain of the antibody heavy chain may be selected accordingly. The light chain constant domain may be a
5 kappa or lambda constant domain.

The constant region is selected according to the functionality required. Normally an IgG1 will demonstrate lytic ability through binding to complement and will mediate ADCC (antibody dependent cell cytotoxicity). An IgG4 will be
10 preferred if a non-cytotoxic blocking antibody is required. However, IgG4 antibodies can demonstrate instability in production and therefore it may be more preferable to modify the generally more stable IgG1. Suggested modifications are described in EP0307434 preferred modifications include at positions 235 and 237. The invention therefore provides a lytic or a non-lytic
15 form of an antibody according to the invention.

Each chain of the antibody may be prepared by CDR replacement. The CDRs of a variable region of a light or heavy chain of a human antibody are replaced by sufficient of the amino acid sequence of each CDR of the anti-CD23
20 antibody that the resulting antibody is capable of binding to the CD23 molecule. The CDR-encoding regions of DNA encoding a hypervariable region of a human antibody chain are replaced by DNA encoding the desired CDRs. If appropriate, this altered DNA is linked to DNA encoding a constant domain for the antibody chain. The DNA is cloned into an expression vector.
25 The expression vector is introduced into a compatible host cell which is cultured under such conditions that the antibody chain is expressed. Complementary antibody chains which are co-expressed in this way may then assemble to form the humanised antibody.

30
There are four general steps to humanise a monoclonal antibody. These are:

- (1) determining the nucleotide and predicted amino acid sequence of the
35 starting antibody light and heavy variable domains;

- (2) designing the humanised antibody, i.e. deciding which antibody framework region to use during the humanising process;
- 5 (3) the actual humanising methodologies/techniques; and
- (4) the transfection and expression of the humanised antibody.

The invention therefore provides a DNA sequence encoding an antibody chain
10 which comprises one or more of the sequences according to:

- | | |
|---|------------------|
| CDRL1 base pair numbers 70-117 of Figure 3 | (SEQ ID NOS: 4) |
| CDRL2 base pair numbers 163-183 of Figure 3 | (SEQ ID NOS: 6) |
| CDRL3 base pair numbers 280-306 of Figure 3 | (SEQ ID NOS: 8) |
| 15 | |
| CDRH1 base pair numbers 91-105 of Figure 4 | (SEQ ID NOS: 10) |
| CDRH2 base pair numbers 148-204 of Figure 4 | (SEQ ID NOS: 12) |
| CDRH3 base pair numbers 301-309 of Figure 4 | (SEQ ID NOS: 14) |

20 or a DNA sequence encoding an antibody chain which comprises one or both of the sequences according to Figures 3 or 4 (SEQ ID NOS: 17 or 18 and SEQ ID NOS 48 and 49).

25 Step 1: Determining the nucleotide and predicted amino acid sequence of the antibody light and heavy chain variable domains

To humanise an antibody only the amino acid sequence of antibody's heavy and light chain variable domains needs to be known. The sequence of the constant domains is irrelevant because these do not contribute to the
30 reshaping strategy. The simplest method of determining an antibody's variable domain amino acid sequence is from cloned cDNA encoding the heavy and light chain variable domain.

There are two general methods for cloning a given antibody's heavy and light
35 chain variable domain cDNAs: (1) via a conventional cDNA library, or (2) via

the polymerase chain reaction (PCR). Both of these methods are widely known. Given the nucleotide sequence of the cDNAs, it is a simple matter to translate this information into the predicted amino acid sequence of the antibody variable domains. In the present instance, the nucleotide sequence and predicted amino acid sequence of the rodent C11 antibody chains are shown in Figures 1 and 2 (SEQ ID NOS: 1 (heavy) and 2 (light) and SEQ ID NOS 46 and 47).

Step 2: Designing the humanised antibody

There are several factors to consider in deciding which human antibody sequence to use during the humanisation. The humanisation of light and heavy chains are considered independently of one another, but the reasoning is basically similar for each.

This selection process is based on the following rationale: a given antibody's antigen specificity and affinity is primarily determined by the amino acid sequence of the variable region CDRs. Variable domain framework residues have little or no direct contribution. The primary function of the framework regions is to hold the CDRs in their proper spatial orientation to recognise antigen. Thus the substitution of rodent CDRs into a human variable domain framework is most likely to result in retention of their correct spatial orientation if the human variable domain framework is highly homologous to the rodent variable domain from which they originated. A human variable domain should preferably be chosen therefore that is highly homologous to the rodent variable domain(s).

A suitable human antibody variable domain sequence can be selected as follows:

1. Using a computer program, search all available protein (and DNA) databases for those human antibody variable domain sequences that are most homologous to the rodent antibody variable domains. The output of a suitable program is a list of sequences most homologous to the rodent antibody, the percent homology to each sequence, and an alignment of

each sequence to the rodent sequence. This is done independently for both the heavy and light chain variable domain sequences. The above analyses are more easily accomplished if only human immunoglobulin sequences are included.

5

2. List the human antibody variable domain sequences and compare for homology. Primarily the comparison is performed on length of CDRs, except CDR3 of the heavy chain which is quite variable. Human heavy chains and Kappa and Lambda light chains are divided into subgroups; Heavy chain 3 subgroups, Kappa chain 4 subgroups, Lambda chain 6 subgroups. The CDR sizes within each subgroup are similar but vary between subgroups. It is usually possible to match a rodent antibody CDR to one of the human subgroups as a first approximation of homology. Antibodies bearing CDRs of similar length are then compared for amino acid sequence homology, especially within the CDRs, but also in the surrounding framework regions. The human variable domain which is most homologous is chosen as the framework for humanisation.

10

15

Step 3: The actual humanising methodologies/techniques

20

An antibody may be humanised by grafting the desired CDRs onto a human framework according to EP-A-0239400. A DNA sequence encoding the desired reshaped antibody can therefore be made beginning with the human DNA whose CDRs it is wished to reshape. The rodent variable domain amino acid sequence containing the desired CDRs is compared to that of the chosen human antibody variable domain sequence. The residues in the human variable domain are marked that need to be changed to the corresponding residue in the rodent to make the human variable region incorporate the rodent CDRs. There may also be residues that need substituting in, adding to or deleting from the human sequence.

25

30

Oligonucleotides are synthesised that can be used to mutagenise the human variable domain framework to contain the desired residues. Those oligonucleotides can be of any convenient size. One is normally only limited

in length by the capabilities of the particular synthesiser one has available. The method of oligonucleotide-directed in vitro mutagenesis is well known.

Alternatively, humanisation may be achieved using the recombinant
5 polymerase chain reaction (PCR) methodology of WO92/07075. Using this methodology, a CDR may be spliced between the framework regions of a human antibody.

10 In general, the technique of WO92/07075 can be performed using a template comprising two human framework regions, AB and CD, and between them, the CDR which is to be replaced by a donor CDR. Primers A and B are used to amplify the framework region AB, and primers C and D used to amplify the framework region CD. However, the primers B and C each also contain, at
15 their 5' ends, an additional sequence corresponding to all or at least part of the donor CDR sequence. Primers B and C overlap by a length sufficient to permit annealing of their 5' ends to each other under conditions which allow a PCR to be performed. Thus, the amplified regions AB and CD may undergo gene splicing by overlap extension to produce the humanised product in a
20 single reaction.

Step 4: The transfection and expression of the reshaped antibody

Following the mutagenesis reactions to reshape the antibody, the mutagenised DNAs can be linked to an appropriate DNA encoding a light or
25 heavy chain constant region, cloned into an expression vector, and transfected into host cells, preferably mammalian cells. These steps can be carried out in routine fashion. A reshaped antibody may therefore be prepared by a process comprising:

- 30 (a) preparing a first replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least a variable domain of an Ig heavy or light chain, the variable domain comprising framework regions from a human antibody and the CDRs required for the humanised antibody of the invention;

- (b) preparing a second replicable expression vector including a suitable promoter operably linked to a DNA sequence which encodes at least the variable domain of a complementary Ig light or heavy chain respectively;
- 5 (c) transforming a cell line with the first or both prepared vectors; and
- (d) culturing said transformed cell line to produce said altered antibody.

10 Preferably the DNA sequence in step (a) encodes both the variable domain and the or each constant domain of the human antibody chain. The humanised antibody can be recovered and purified. The cell line which is transformed to produce the altered antibody may be a Chinese Hamster Ovary (CHO) cell line or an immortalised mammalian cell line, which is advantageously of lymphoid origin, such as a myeloma, hybridoma, trioma or

15 quadroma cell line. The cell line may also comprise a normal lymphoid cell, such as a B-cell, which has been immortalised by transformation with a virus, such as the Epstein-Barr virus. Most preferably, the immortalised cell line is a myeloma cell line or a derivative thereof. The expression system of choice is the glutamine synthetase expression system described in WO87/04462.

20 Although the cell line used to produce the humanised antibody is preferably a mammalian cell line, any other suitable cell line, such as a bacterial cell line or a yeast cell line, may alternatively be used. For single antibody chains, it is envisaged that E. coli - derived bacterial strains could be used. The antibody

25 obtained is checked for functionality. If functionality is lost, it is necessary to return to step (2) and alter the framework of the antibody.

The invention therefore provides an expression vector comprising DNA encoding and adapted for the expression of an antibody according to the

30 invention and host cells transformed with said expression vectors.

Once expressed, the whole antibodies, their dimers, individual light and heavy chains, or other immunoglobulin forms of the present invention can be purified according to standard procedures of the art, including ammonium sulfate

35 precipitation, affinity columns, column chromatography, gel electrophoresis

and the like (see, generally, Scopes, R., Protein Purification, Springer-Verlag, N.Y. (1982)). Substantially pure immunoglobulins of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, an antibody may then be used therapeutically or in developing and performing assay procedures, immunofluorescent stainings, and the like (See, generally, Immunological Methods, Vols. I and II, Lefkovits and Pernis, eds., Academic Press, New York, N.Y. (1979 and 1981)).

10 The antibody may function by blocking the interaction between membrane bound CD23 and a ligand which binds to it. In vitro assays e.g. radio-immune assays may be used to study such a blocking effect. The antibody may also function by binding to soluble CD23. Membrane bound CD23 is known to undergo cleavage from the cell surface leading to the formation of a number of
15 soluble fragments. These fragments act like cytokines and play a major role in IgE formation. Excessive levels of soluble CD23 have therefore been implicated in disease. By binding to these fragments the antibodies according to the invention can interfere with the ability of the soluble CD23 to mediate its effects. The antibodies according to the invention are also believed to prevent
20 soluble CD23 production by preventing cleavage of the membrane bound receptor. The invention therefore provides the use of an anti-CD23 antibody in the manufacture of a medicament for blocking soluble CD23 formation.

The ability of any antibody to mediate its effect will be related to its affinity for the target antigen. Antibodies according to the invention have a very high
25 affinity for the CD23 receptor. The affinity constant of such antibodies is preferably greater than $1 \times 10^9 \text{ Ka Mo}^{-1}$ and more preferably greater than $1 \times 10^{10} \text{ Ka Mo}^{-1}$. This invention therefore provides antibodies capable of binding the CD23 receptor or soluble CD23 characterised by an affinity
30 constant equal to or greater than $1 \times 10^9 \text{ Ka Mo}^{-1}$.

Antibodies which bind to the CD23 receptor can be used in vivo in the treatment or prophylaxis of inflammatory or autoimmune diseases. This is of great significance given the fact that many of these diseases are difficult or
35 impossible to treat effectively, despite long standing research into their

research into their nature causes. This is particularly the case in respect of arthritis, which often affects people in middle age and can cause them to give up work prematurely. An effective treatment of arthritis has been a long standing goal of many research groups.

5

The antibodies of the present invention are believed to be useful in the treatment or prophylaxis of several diseases including arthritis, lupus erythematosus, Hashimotos thyroiditis, multiple sclerosis, diabetes, uveitis, dermatitis, psoriasis, urticaria, nephrotic syndrome, glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, sjogren's syndrome, allergies, asthma more specifically, allergic or intrinsic asthma, acute asthmatic exacerbation, rhinitis, eczema, GVH, COPD, insulinitis, bronchitis (particularly chronic bronchitis) or diabetes (particularly Type 1 diabetes).

15

The present invention therefore provides the use of an antibody according to the invention in the manufacture of a medicament for the treatment of any one or more of the above disorders. The invention also provides a method for the treatment of one or more of the above disorders comprising the administration of a therapeutically effective dose of an antibody according to the invention.

20

Antibodies according to the invention may also be useful in studying the interactions between CD23 and various ligands e.g. between CD23 and CD21, between CD23 and CD11b, between CD23 and CD11c, between CD23 and an 80 to 85 KDa endothelial cell protein(which may be an 80 or 85 KDa endothelial cell protein) or between CD23 and a 115 KDa protein (which is believed to be related to the 80 to 85 KDa endothelial protein). One or more of the above interactions are believed to occur in vivo. Antibodies or other binding agents which are capable of blocking these interactions are particularly preferred since it is believed that they may be especially suitable for reducing or alleviating cytokine mediated inflammatory effects. They may be useful against B-cell malignancies such as chronic lymphocytic leukaemia, and hairy cell leukaemia.

25

30

An alternative mechanism of action of anti CD23 therapy could involve the blocking of an IgE immune response.

5 Antibodies of this invention are also of particular use in the treatment of prophylaxis of allergic diseases, including non-IgE mediated diseases. They may be used in the treatment and prophylaxis of ulcerative colitis. They may also be used in the treatment and prophylaxis of Crohn's disease.

10 The antibodies of the present invention may be used alone or in combination with immunosuppressive agents such as steroids, cyclosporin, or antibodies such as an anti-lymphocyte antibody or more preferably with a tolerance-inducing, anti-autoimmune or anti-inflammatory agent such as a CD4+T cell inhibiting agent e.g. an anti-CD4 antibody (preferably a blocking or non-depleting antibody), an anti-CD8 antibody, a TNF antagonist e.g. an anti-TNF
15 antibody or TNF inhibitor e.g. soluble TNF receptor, or agents such as NSAIDs.

20 Suitable dosages of the substance of the present invention will vary, depending upon factors such as the disease or disorder to be treated, the route of administration and the age and weight of the individual to be treated. Without being bound by any particular dosages, it is believed that for instance for parenteral administration, a daily dosage of from 0.01 to 20 mg/kg of a
25 antibody of the present invention (usually present as part of a pharmaceutical composition as indicated above) may be suitable for treating a typical adult. More suitably the dose might be 0.1 to 5 mg/kg, such as 0.1 to 2 mg/kg. A unit dose suitably be will be 1-400 mg.

30 The antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic or immunosuppressive agents. Typically, the agents will include cyclosporin A or a purine analog (e.g., methotrexate, 6-mercaptopurine, or the like), but numerous additional agents (e.g., cyclophosphamide, prednisone, etc.) well-known to those skilled in the art may also be utilised.

If it is desired to lyse the cells to which the antibody binds, an antibody of the present invention may form part of an immunotoxin. Immunotoxins are characterised by two components and are particularly useful for killing selected cells in vitro or in vivo. One component is a cytotoxic agent which is usually fatal to a cell when attached or absorbed. The second component, known as the "delivery vehicle", provides a means for delivering the toxic agent to a particular cell type, such as cells comprising a carcinoma. The two components are commonly chemically bonded together by any of a variety of well-known chemical procedures. For example, when the cytotoxic agent is a protein and the second component is an intact immunoglobulin, the linkage may be by way of heterobifunctional cross-linkers, e.g., SPDP, carbodiimide, glutaraldehyde, or the like. Production of various immunotoxins is well-known with the art, and can be found, for example in "Monoclonal Antibody-Toxin Conjugates: Aiming the Magic Bullet", Thorpe et al, Monoclonal Antibodies in Clinical Medicine, Academic Press, pp. 168-190 (1982).

A variety of cytotoxic agents are suitable for use in immunotoxins. Cytotoxic agents can include radionuclides, such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatin; and cytotoxic proteins such as ribosomal inhibiting proteins like pokeweed antiviral protein, Pseudomonas exotoxin A, ricin, diphtheria toxin, ricin A chain, etc., or an agent active at the cell surface, such as the phospholipase enzymes (e.g., phospholipase C). See, generally, "Chimaeric Toxins," Olsnes and Phil, Pharmac. Ther., 25:335-381 (1982), and "Monoclonal Antibodies for Cancer Detection and Therapy," eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985).

The delivery component of the immunotoxin is an antibody according to the present invention. Intact immunoglobulins or their binding fragments, such as Fab, are preferably used. Typically, the antibodies in the immunotoxins will be of the human IgA, IgM or IgG isotype, but other mammalian constant regions may be utilised as desired.

The invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an antibody according to the invention. The composition may comprise an immunotoxin according to the invention. The antibody, immunotoxin and pharmaceutical compositions thereof of this invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly or intravenously.

The compositions for parenteral administration will commonly comprise a solution of the antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilised by conventional, well known sterilisation techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjustment agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentration of antibody in these formulations can vary widely, for example from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Thus, a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 50 mg of antibody. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania (1980).

The antibodies of this invention can be lyophilised for storage and reconstituted in a suitable carrier prior to use. This technique has been shown

to be effective with conventional immune globulins. Any suitable lyophilisation and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.

Antibodies of the present invention can further find a wide variety of utilities in vitro. By way of example, the exemplary antibodies can be utilised for T-cell typing, for isolating specific CD23 antigen bearing cells or fragments of the receptor, for vaccine preparation, or the like.

For diagnostic purposes, the antibodies may either be labelled or unlabelled. Unlabelled antibodies can be used in combination with other labelled antibodies (second antibodies) that are reactive with the humanised antibody, such as antibodies specific for human immunoglobulin constant regions. Alternatively, the antibodies can be directly labelled. A wide variety of labels may be employed, such as radionuclides, fluors, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens), etc. Numerous types of immunoassays are available and are well known to those skilled in the art.

Kits can also be supplied for use with the subject antibodies in the protection against or detection of a cellular activity or for the presence of a selected antigen. Thus, an antibody of the present invention may be provided, usually in a lyophilised form in a container, either alone or in conjunction with additional antibodies specific for the desired cell type. The antibodies, which may be conjugated to a label or toxin, or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilisers, biocides, inert proteins, e.g., serum albumin, or the like, and a set of instructions for

use. Generally, these materials will be present in less than about 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% wt. of the total composition. Where a second antibody capable of binding to the chimaeric antibody is employed in an assay, this will usually be present in a separate vial. The second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.

Figures

- Figure 1 shows the amino acid and nucleotide sequences of the murine C11 heavy chain variable region.
- Figure 2 shows the amino acid and nucleotide sequences of the murine C11 light chain variable region.
- Figure 3 shows the amino acid and nucleotide sequences of the humanised anti-CD23 antibody heavy chain variable region.
- Figure 4 shows the amino acid and nucleotide sequences of the humanised anti-CD23 antibody light chain variable region.
- Figure 5 shows the half maximal binding of chimaeric CD23 IgG1m
- Figure 6 shows the half maximal binding of humanised CD23 IgG1m
- The following Examples illustrate the invention.

Cloning and Sequencing of the murine anti-CD23 monoclonal antibody C11

General methodology

Unless otherwise stated, the following standard procedures and conditions were used. Manufacturers' recommended protocols were followed where applicable. Restriction digestions and other routine molecular biology procedures were performed essentially as described by Maniatis et al ("Molecular Cloning - a laboratory manual" 2nd edition, Cold Spring Harbour Press).

PCR was performed using a programmable thermal cycler (Trio; Biometra). A typical 100 µl reaction contained 2.5 units of AmpliTaq polymerase (Perkin-Elmer-Cetus, Beaconsfield, UK) in the buffer supplied by the manufacturer; 250 µM each of dATP, dCTP, dGTP and dTTP; amplification primers at 1 µM and template DNA. Unless otherwise noted, the following cycle specifications were used:

Step 0: 95°C for 5 minutes
Step 1: 95°C for 1 minute
Step 2: 50°C for 1 minute, ramping up to step 3 at 0.4°C/s
Step 3: 72°C for 1 minute, go to step 1, repeating the loop 30 times
Step 4: 72°C for 5 minutes

DNA sequencing was performed using the dideoxy terminator method using either the Sequenase v2 system (USB, Cambridge, UK) or the fluorescent dye-terminator system (ABI).

Gel purification of DNA was performed by separation of the reaction on a low-melting point agarose gel (NuSieve GTG, FMC, Rockland, ME). The chosen fragment was excised under UV illumination, and the DNA recovered using a Wizard PCR Preps kit (Promega, Southampton, UK).

Numbering of amino-acid residues in antibody chains follows the scheme of Kabat et al ("Sequences of proteins of immunological interest", US Dept of Health and Human Services, US Govt Printing Office, 1991).

Preparation of cDNA from C11 hybridoma

A growing culture of C11 cells was used for RNA extraction. A culture containing 1.3×10^7 cells were centrifuged and both cell pellet and supernatant retained for analysis. The supernatant was tested for the presence of murine immunoglobulin of various isotypes by an immunological method (ISO1 kit; Sigma, Poole, UK) and the C11 monoclonal was found to be of isotype IgG1.

Messenger RNA was isolated from the cell pellet by sequential application of a Total RNA Isolation Kit (Stratagene, Cambridge, UK) (producing total RNA) and then a mRNA Purification Kit (Dyna, Oslo, Norway). Portions of both the mRNA and the total RNA were then converted to single-stranded cDNA using the Superscript Preamplification System (BRL, Paisley, Scotland, UK). Aliquots of the resulting cDNA were used in PCRs designed to separately amplify the variable regions of the C11 immunoglobulin heavy and light chains.

15 Cloning and sequencing of the C11 heavy chain variable region

The heavy chain was cloned by a variation of the method of Bendig and Jones (Bio/Technology 9:88-89) in which 12 forward primers specific to the signal peptide region of the heavy chain message and 1 reverse primer specific for the mouse $\gamma 1$ constant region are used in a PCR to amplify the entire variable region. Rather than add all 12 forward primers to a single reaction, 12 separate PCRs were performed, each using one of the forward primers in combination with the $\gamma 1$ reverse primer. These reactions were performed with an annealing temperature of 42.5°C (Step 2 in the scheme above).

Samples of each reaction were analysed on an agarose gel, and a band of the expected size seen only in the reaction that used the forward primer MHV11. Based on this result, two PCRs using MVH11 and the $\gamma 1$ reverse primer were performed using cDNA derived from mRNA and from total RNA respectively. The use of two independent PCRs to serve as a source of material for cloning is a common device well known in the art for the avoidance of sequence errors caused by misincorporation of nucleotides by Taq polymerase.

The resulting PCR fragments were digested with XmaI and Sall, gel purified, and then cloned into pUC18. The inserts from a number of clones from each

PCR were sequenced and found to be identical, suggesting that the sequence does not contain errors introduced by the PCR process. The complete sequence of the variable region is shown in Figure 1 (SEQ ID 1), and is a perfect match to the Kabat Group IIIC heavy chain consensus.

5

Cloning and sequencing of the C11 light chain variable region

The C11 light chain variable region was cloned by a similar process, again involving a set of 11 forward primers specific for the signal peptide region of the light chain message and 1 reverse primer specific for the mouse κ constant region (Bendig and Jones, *op cit*). Additionally, as we have previously determined that this primer set does not efficiently amplify all mouse kappa light chains, we included another primer, here termed MKV12 (sequence 5' ACTAGTCGACATGAAGTTTCCTTCTCAACTTCTGCTC3') (SEQ ID 41). As above, separate PCRs, each including one forward primer and the κ constant reverse primer, were performed, and analysed by agarose gel electrophoresis.

Three of the reactions produced products of the expected size. These were separately digested with Sall and XmaI, purified, and cloned into pUC18 to yield clones designated VKI, VKJ and VKK. These were partially sequenced to determine their identity. Partial sequence for clone VKI was found to be identical with a known sequence, a light chain derived from the MOPC21 myeloma which has a frameshift in CDR3 (Genbank M35669), and so VKI was discarded. Partial sequence for clone VKK, including CDR3, was found to be identical with the productively rearranged MOPC21 light chain (Genbank J00560, J00552). This of itself does not preclude the VKK clone from being the correct C11 light chain as both light chains may share CDR3 in the germline configuration, but given that the myeloma parent of the hybridoma was known to be a MOPC21 derivative, and that another MOPC21 related sequence had already been identified (clone VKI), clone VKK was thought unlikely to be correct.

Clone VKJ was considered most likely to represent the true C11 light chain variable region, as the partial sequence was not identical with any sequence in Genbank. VKJ was sequenced fully, and found to be a fully-functional light

35

chain sequence, without frameshifts, most likely using the VK167 or VK24 genes, placing it as an atypical Kabat group II sequence. The complete sequence of the VKJ clone is shown in Figure 2 (SEQ ID 2). A second independent PCR using the primer pair that produced the VKJ clone was also performed, and the product cloned and sequenced as above to preclude the possibility that the VKJ sequence contained PCR errors. Clones from this second amplification had a sequence identical to the original VKJ clone.

Definitive proof that VKJ contained the C11 light chain variable region was obtained through the construction of a chimaeric antibody using this VK and the VH described above. This antibody was shown to bind CD23.

Designing the chimaeric antibody

To verify that the correct heavy and light chain variable regions had been cloned and sequenced, a chimaeric anti-CD23 was constructed. The heavy chain variable region was amplified using the clones from the cDNA library. The forward primer contained the 5' cloning site (Hind III), 5' untranslated sequence including a functional Kozac signal, together with the first six codons of the murine variable heavy region. The reverse primer engineers a Spe I site into Framework 4 in frame to fuse to a human gamma I constant region. These primers generated a 430 base pair product.

Heavy chain anti-CD23 chimaeric PCR oligos

5' gAT gAA gCT TTA CAg TTA CTC AgC ACA CAg gAC CTC ACC ATg gAT
TTT ggg CTg ATT 3' SEQ ID 19

5' gAT ggA CTA gTg TCC CTT ggC CCC A 3' SEQ ID 20

The primers for amplification of the anti-CD23 light chain variable region to make chimaeric light chain were constructed containing the 5' cloning site (Hind III), 5' untranslated sequence including a functional Kozac signal, together with the first six codons of the murine variable light chain. The reverse primer contained a BsiW 1 site and anticodons for the indicated

amino acids. The redundancy codes are standard: Y = T or C; K= T or G; V = A, G or C. The product was 420 base pairs.

Light chain anti-CD23 chimaeric PCR oligos

5

5' gAT gAA gCT TTA CAg TTA CTC AgC ACA CAg gAC CTC ACC ATg Agg
TTC TCT gTT CAg 3' SEQ ID 21

10

5' gAT gCg TAC gTY TKA TYT CCA VCT TKG T 3' SEQ ID 22 (and SEQ ID
NOS 42 to 45 and 52 and 53)

T R K I E L K T
R V

15

The heavy chain PCR products were cleaned, cut with Hind III and Spe I, then
cloned into a pUC vector cut with Hind III and Spe I containing a human
gamma I constant region. The human constant region used was the IgG1
heavy chain described in Reichmann L et al (1988) Nature 322, 323-327 but in
cDNA context as described in Page, M. J. and Sydenham, M. A. (1991)
Biotechnology 9, 64-68 and Crowe J. S. et al Clinical Exp Immunol (1992) 87
105.

20

The variable and constant region was removed from the pUC vector with Hind
III and Eco R1, then cloned into the Hind III - Eco R1 site of the expression
vector pEE6 obtained from Celltech (Stephens & Cockett and Nucl. Acids.
Res. (1989) 17, 7110).

25

When the heavy chain chimaeric was sequenced, 100 base pairs of 5'
sequence were missing. Upon examination of the murine variable heavy
chain sequence, an internal Hind III site was observed. To create the
complete heavy chain variable sequence generated in the PCR products, the
PCR product was digested with Hind III and the small 100 base pair fragment
cloned into a Hind III digested pEE6 containing the chimaeric anti-CD23 heavy
chain.

30

35

The light chain PCR products were cleaned, then cut with Hind III and BsiW 1,
then ligated into a pUC vector containing the human kappa constant region.

The human kappa constant region used was as described in Reichmann et al Nature 1988 (*supra*). The light chain variable and constant region was removed from the pUC vector with Hind III and Eco R1. This fragment was cloned into the Hind III - Eco R1 site of the expression vector pEE12 obtained from Celltech (Bebington and Hentschel, In DNA cloning Vol 3, Chapter 8 IRL PRESS 1987).

The chimaeric heavy chain was isolated as a Bgl II - Sal I cassette and inserted at the Bam H1 - Sal I site of the pEE12 light chain plasmid, such that the light and heavy chain genes were in the same plasmid.

The final expression plasmid containing the chimeric CD23 was transiently expressed in COS cells (green monkey kidney cells) as follows. Transfectam (Promega) was reconstituted to 1mg/ml according to the recommended protocol of the manufacturer. On the day prior to transfection, 5.0×10^5 cells per well were plated in a six well plate (Costar) in a total volume of 2.5 ml of media. Medium was Dulbecco's Modified Eagle Medium (Gibco/BRL) and 10% dialysed fetal calf serum (Hyclone). The plates were incubated overnight at 37°C. For each well in the 6-well plate, 20µl of Transfectam was added to 0.5 ml of serum free media in a sterile polystyrene bijoux container, then vortexed briefly. For each well to be transfected, 4 µg of plasmid DNA was added to the 0.5ml of Transfectam solution in serum free media, then mixed well and left at room temperature for about 10 minutes while preparing the cells for transfection. Medium was aspirated from the cells to be transfected, then the cells were carefully rinsed 1 or 2 times with 5 ml pre-warmed serum free media per well, and then 0.5 ml of serum free media was added to each well. Previously prepared 0.5 ml DNA/Transfectam solution was added into each well and when all wells completed, the plate was gently swirled to ensure mixing. The plate was returned to the incubator for 4 hours. Two ml of complete medium (containing 1.5 times the normal serum concentration) was added to the transfection solution. The plates were returned to the incubator for three days when the medium was harvested from the plates, and assayed for antibody activity.

The chimaeric antibody bound sCD23 in an ELISA assay. For the ELISA assay to determine sCD23 binding, EIA/RIA plates (Costar) were coated with 100 μ l/well of 2 μ g/ml sCD23 in 35 mM NaHCO₃, 15 mM Na₂CO₃, pH 9.3 overnight at 4 °C. Plates were washed three times with 150 mM NaCl, 50 mM Trizma base, 0.1% (v/v) Tween-20, pH 7.4 (TBS/Tween), blocked for 1-2 hours at 22 ° C with 100 μ l/well of 2% bovine serum albumin in TBS/Tween, and washed three times with TBS/Tween.

Dilutions of supernatants from the murine hybridoma C11 were added 100 μ l/well on one part of the 96 well plate and dilutions of the chimaeric anti-CD23 antibody transiently expressed in the supernatants of COS cells was added to another part of the 96 well plate. The C11 murine antibody was detected with anti-mouse IgG (whole molecule) peroxidase conjugate developed in goat from Sigma A4416, diluted 1:1000 in PBS/BSA(bovine serum albumin) (1%). The chimaeric anti-CD23 antibody was detected with anti-human kappa light chain (bound and free) peroxidase conjugate, (Sigma A-7164), diluted 1:5000 in PBS/BSA (1%). Chimaeric anti-CD23 was positive for binding sCD23 in the ELISA.

The chimaeric anti-CD23 was also positive in binding membrane CD23 as determined by FACS. These data verified that the correct murine C11 heavy and light chain variable regions had been cloned and sequenced. These murine sequences were then used to develop the humanised anti-CD23 antibody.

Construction of the humanised heavy and light chain genes

The humanised heavy and light chains were constructed following the method of Lewis and Crowe (Gene 101, 297-302, 1991).

(i) Light Chain

The mouse framework variable region sequences were compared to human framework sequences in the GenBank database.

Light chain human frameworks were compared for homology to the mouse anti-human anti-CD23 light chain variable framework sequence. The framework most homologous was chosen as template for PCR overlap extension; it was:

5

Locus: HSIKVII 490 bp mRNA

Definition: Human rearranged DNA for kappa-immunoglobulin leader peptide and variable region

Source: homo sapiens

10

Authors: Klobbeck, H.G. et al. Contribution of human V kappa II germ-line genes to light chain diversity, Nature, 309, 73-76, 1984.

15

Each amino acid that differed at the same position in the mouse and human framework was examined. The human amino acid was kept if the antigen binding is not affected because human residues should be less immunogenic than a mouse residue. The identification of specific residues that affect binding has to be hypothetical and based on data from other antibody-antigen interactions. From published data, residues 71, 91, and 94 in the heavy chain framework have been shown to interact with antigen binding (Tramontano, A., Chothia, C., and A.M. Lesk, J. Mol. Biol., 215, 175-182, 1990.; Kettleborough, C.A., Saldanha, J., Heath, V.J., Morrison, C.J. and M.M. Bendig, Protein Eng, 4, 773-783, 1991). These residues should therefore, be the same in the humanised framework as in the mouse framework. Each amino acid change is considered for size, hydrophobicity, hydrophilicity, and charge. If the human amino acid is similar to the mouse amino acid in these characteristics, then the human amino acid is used at this site.

25

30

There were 13 differences between the amino acid sequence of the mouse light chain variable framework sequence and the most homologous human variable light chain sequence. None of the mouse residues were retained. A humanised light chain variable sequence was generated and a GCG program was used to identify silent sites for the following enzymes:

AccI; HaeI; NheI; PvuII; XbaI; XhoI; XmaI

Changes in the nucleotide sequence were made to include these restriction enzyme sites without changing the amino acid sequence. The presence of these sites were included to make cutting and pasting fragments of PCR clones easier.

5

The humanised variable light chain was generated by grafting the mouse light chain CDRs onto an existing template (eg HSIKGVII Klobek, H. G. et al Nature (1984) 309, 73-76) containing the chosen human light chain framework sequence using splice overlap PCR. (Crowe, *et al. supra.*) Plasmids encoding the humanised light chain variable sequences were developed as follows:

10

A Kozac sequence for transcription and a signal sequence (MGWSCIIILFLVATATGVHS - SEQ ID 15) is included in the light chain template sequence. A HindIII site was added at the 5' end and a BswI site added at the 3' end of the PCR product for cloning. The oligos for PCR overlap extension were:

15

A_L:SEQ ID NO: 23 5' gAT CAA gCT TCT CTA CAg TTA CTg AgC ACA 3'

20

B_L:SEQ ID NO: 24. 5' AAT CAA gTA TgT CTT CCC ATC CTT ATA CAg gAg ACT CTT ACT CgA gCg ACA ggA gAT ggA ggC 3'

C_L:SEQ ID NO: 25. 5' CgC TCg AgT AAg AgT CTC CTg TAT AAg gAT ggg AAg ACA TAC TTg AAT Tgg TAC CTg CAg AAg 3'

25

D_L:SEQ ID NO: 26. 5' TgA TgC CCg ggT ggA CAT CAA ATA gAT CAg gAg CTg 3'

E_L:SEQ ID NO: 27. 5' TTg ATg TCC ACC Cgg gCA TCA ggg gTC CCT gAC Agg 3'

30

F_L:SEQ ID NO: 28. 5' AgC CAC CTg ACg TTT gAT CTC CAC CTT ggT CCC TTg

gCC gAA CgT gAA Tgg ATA CTC TAC CAg CTg TTg ACA gTA ATA AAC CCC 3'

35

PCR reactions (Saiki *et al.* Science 239, 487-491, 1988) were performed in a programmable heating block (Perkin Elmer, GeneAmp 9600) using 25 rounds of temperature cycling (94°C for 1 minute, 50°C for 2 min, and 72°C for 3 min) followed by a final 5 min step at 72°C. Primers (at 40uM concentration each), a specified amount of template, and 2.5 units of Taq polymerase (Perkin Elmer Cetus) were used in a final volume of 50ul with the reaction buffer as recommended by the manufacturer.

Three primary PCR reactions were initially carried out, with 10ng of template per reaction, using the primer pairs A_L with B_L, C_L with D_L, E_L with F_L respectively. The products of these PCR reactions, fragments AB_L, CD_L and EF_L respectively, were purified using Qiaquick PCR Purification Kit (Qiagen Ltd, Surrey, UK, product #28104) following the protocol recommended by the manufacturer. Fragments AB_L and CD_L were combined using one tenth of each purified product, and subjected to recombinant PCR reactions with primers A_L and D_L. The product of this reaction, fragment AD_L was purified as above, and one tenth of the product was combined in a recombinant PCR reaction with one tenth of purified EF_L using primers A_L and F_L. The final humanised light chain recombinant PCR product, AF_L, was ligated into pCRTM II from "TA Cloning Kit" (Invitrogen BV, Leek, The Netherlands, product #K2000-01) following the protocol recommended by the manufacturer. Plasmid isolates were sequenced using the ABI fluorescent sequencer.

(ii) Heavy Chain

The human framework sequence most homologous to the mouse framework sequence was identified for the heavy chain. The most homologous sequence in the database for the heavy chain was:

Locus: HUMSIGVS 423 BP MRNA

Definition: Human Ig mu-chain mRNA V3b-D-J4 region 5' end

Source: Homo sapiens cDNA to mRNA

Authors: Sanz, I. et al. VH sequence of a human autoantibody. Evidence that autoantibodies can be unmutated copies of germline genes. J. Immuno. 142, 883-887, 1989.

5 There were seventeen differences between the amino acid sequence of the mouse heavy chain variable framework sequence and the most homologous human variable heavy chain framework sequence. In five positions 49, 66, 76, 77 and 94 the mouse amino acid was retained. At all other positions the human amino acid was used for the humanised heavy chain framework.

10 A file of the humanised heavy chain variable sequence was generated and a GCG program was used to identify silent sites for the following enzymes: EagI; NheI; XbaI; XhoI; XmaI

15 Changes in the nucleotide sequence were made to include these restriction enzyme sites without changing the amino acid sequence. The presence of these sites were included to make cutting and pasting fragments of PCR clones easier.

20 A HindIII restriction site for cloning, a Kozac sequence for transcription initiation, and a murine signal sequence (MAVWVWTLFLMAAAQSAQA - SEQ ID 16) for protein secretion were added to the 5' end of the humanised heavy chain variable region sequence. An SpeI restriction site was added to the 3' end for cloning.

25 The humanised variable heavy chain framework with mouse CDRs was built by PCR using long overlapping oligonucleotides. Eight oligos were synthesised approximately 60 base pairs with 15 base pair overlaps. The oligos were as follows:

30 AH:SEQ ID NO 29. 5' ACA CgA AgC TTC ACC ATg gCT Tgg gTg Tgg ACC TTg CTA TTC CTg ATg gCg gCC gCC CAA 3'

35 BH:SEQ ID NO 30: 5' CTT TAC CAA gCC TCC CCC AgA CTC CAC CAg CTg CAC CTC TgC TTg ggC ACT TTg ggC ggC CgC CAT 3'

CH:SEQ ID NO 31: 5' TTg gTA AAg CCC ggg ggg TCC CTT AgA CTC TCC
TgT gCA gCT AgC ggA TTC ACT TTC AgT 3'

5 DH:SEQ ID NO 32: 5' CCC CTT CCC Tgg AgC CTg gCg gAC CCA ggA CAT
CCA gTA gCC ACT gAA AgT gAA TCC gCT 3'

EH:SEQ ID NO 33: 5' ggg AAg ggg CTC gAg Tgg gTT gCT gAA ATT AgA
TTg AAA TCT gAT AAT TAT gCA ACA CAT 3'

10

FH:SEQ ID NO 34: 5' ATC ATC TCT TgA gAT ggT gAA TTT CCC CTT CAC
AgA CTC CgC ATA ATg TgT TgC ATA ATT 3'

15 GH:SEQ ID NO 35: 5' ATC TCA AgA gAT gAT TCA AAA TCT AgA CTg TAT
CTg CAA ATg AAC AgC CTg AAA ACC gAg gAC ACA 3'

HH:SEQ ID NO 36: 5' ggT gAC TAg TgT TCC CTg gCC CCA gTC TAT gAA
ATC TgT ACA gTA ATA CAC ggC TgT gTC CTC ggT TTT 3'

20 The murine CDR's were grafted on to the template using recombinant PCR.
PCR was performed using a programmable thermal cycler (Trio; Biometra).
A 50 μ l reaction contained 2.5 units of AmpliTaq polymerase (Perkin-Elmer-
Cetus, Beaconsfield, UK) in the buffer supplied by the manufacturer, a buffer
25 which provides the preferred pH and ionic strength for amplification (10 mM
Tris-HCl, pH 8.3, 50 mM KCl and 1.5 mM MgCl₂), 200 μ M each of dATP,
dCTP, dGTP, and dTTP, and amplification primers at 1 μ g/ μ l. The samples
were heated to 94°C for 2 minutes in a heating block, then centrifuged for 30
seconds at 16,000xG. Samples were placed on ice for 1 minute, then Taq
polymerase and a drop of mineral oil added to each sample. The samples
30 were vortexed, then centrifuged for 30 seconds at 16,000xG. Samples were
placed in the thermal cycler programmed as follows:

Step 1: 94°C for 1 minute

Step 2: 50°C for 2 minutes, ramping up to step 3 at 0.4°C/second

35 Step 3: 72°C for 3 minutes, go to step 1 repeating the loop 25 times

Seven primary PCR reactions were initially performed with 1 µg/µl of each primer per reaction, using the primer combinations A_H and B_H, C_H and D_H, E_H and F_H, G_H and H_H; A_H B_H C_H and D_H, E_H F_H G_H and H_H; A_H B_H C_H D_H E_H F_H G_H and H_H. A 1 ul aliquot of the primary PCR reaction products were combined with primers (1 ug/ul) and subjected to the same PCR reaction conditions described for the primary PCR reactions to generate the full length heavy chain variable region. Primary PCR reaction fragments A_{FH} and E_H fragment, A_H, fragments A_{BH}, G_H, and A_H, fragments A_{BH}, C_{DH}, E_{FH}, and G_H, fragments A_{BH}, C_{DH}, E_{FH}, G_H, and A_H were combined with primers A_H and H_H. All of the PCR reactions produced full length fragments. The humanised heavy chain variable region PCR product from the A_{BH}, G_H, and A_H reaction was purified using Wizard PCR Preps DNA Purification System (Promega) following the protocol recommended by the manufacturer. The purified products were cut with Hind III and Spe I then cloned into a pUC vector containing a mutated IgG1 constant region (see below).

Construction of the Humanised antibody

The humanised heavy chain variable region PCR products were cut with Hind III and Spe I then cloned into a pUC vector containing a mutated IgG1 constant region (see below). The variable region of the clones were sequenced Figures 3 and 4 (SEQ IDS 17 and 18). A clone containing the correct humanised heavy chain variable amino acid sequence was selected. This clone had one silent nucleotide change from the model humanised heavy chain variable sequence.

An IgG1 with mutations to eliminate C1q and Fc binding was used for the constant region of the humanised heavy chain. These mutations were based on the following two papers: Duncan, A.R. and Winter, G. Localization of the C1q binding site on antibodies by surface scanning. *Nature* 332, 738-740, 1988 and Duncan, A.R., Woolf, J.M., Partridge, L.J., Burton, D.R. and Winter, G. Localisation of the binding site for human FcR1 on IgG. *Nature* 332, 563-564, 1988.

The residues mutated are shown in Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S. and C. Foeller, 1991, Sequences of Proteins of Immunological Interest, Volume 1, page 680.

5 The changes made in IgG1 to create an IgG1 isotype lacking cytotoxicity were as follows: 248 Leu (CTg) to Ala (gCg) and 250 Gly (ggA) to Ala (gCA).

10 These mutations were made by site directed mutagenesis of a human IgG1 as follows:

Constant region PCR oligos used to generate IgG1 with mutations were:

15 SEQID 37 A_c gCT gCT CCT TTT AAg CTT Tgg ggT CAA ggC TCA CTA gTC
ACA gTC TCC

SEQID 38 B_c TgA Cgg TgC CCC CgC gAg TTC Agg

20 SEQID 39 C_c CCT gAA CTC gCg ggg gCA CCg TCA

SEQID 40 D_c AAg CTT CCg TCg AAT TCA TTT ACC Cgg AgA CAg

25 Oligo A_c contains a Hind/Spel site. Oligos B_c and C_c contain the mutations at positions 248 and 250. Oligo D_c contains an Eco R1 site. Oligos A_c and B_c were used to generate a fragment AB using the PCR conditions specified in the General Methodology section of this application and a cloned human IgG1 constant region as template (Reichmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy, *Nature* 322, 323-327). Oligos C_c and D_c were used to generate fragment CD using the same
30 PCR conditions and template as for AB. PCR fragments AB and CD were cleansed using a Wizard PCR Preps DNA Purification System (Promega). PCR fragments AB (5.0 ul) and CD_c (5.0ul) were combined with oligos A_c and D_c to generate a fragment AD_c containing the IgG1 constant region with mutations. Fragment AD_c was cleaned by Wizard PCR Preps DNA Purification
35 System (Promega), digested with HindIII and Eco R1, then ligated into HindIII-

EcoR1 digested pEE6 plasmid containing the humanised anti-CD23 heavy chain variable region.

5 The constant region was sequenced to confirm the mutations. A fragment containing these mutations was transferred to an expression plasmid pEE6 containing the humanised anti-CD23 heavy chain variable region.

10 The humanised light chain variable region PCR products were cut with Hind III and BsiW 1, then cloned into expression plasmid pEE12 containing the human kappa light chain constant region described above. The clones were sequenced using an ABI fluorescent sequencer and a clone containing the correct amino acid sequence for humanised light chain variable region was selected.

15 A Bgl II - Sal I fragment containing the humanised heavy chain anti-CD23 from the pEE6 plasmid was ligated into the Bam H1 - Sal I site of the pEE12 plasmid containing the humanised light chain anti-CD23 to make one plasmid containing both the humanised heavy and light chain anti-CD23. The humanised heavy chain variable and constant region and the humanised light
20 chain variable and constant region in the final expression plasmid were sequenced.

Transient Expression of Humanised Antibody

25 The plasmid with the humanised anti-CD23 was transfected into COS cells and transiently expressed using the same protocol as described for the chimaeric antibody above. The expression plasmid with the humanised anti-CD23 was transfected into COS cells and transiently expressed as described for the chimeric anti-CD23 transient expression.

30 The concentration of chimeric and humanised anti-CD23 antibody required for half-maximal binding to sCD23 was assayed using the sCD23 ELISA already described. Absorbance at 405 nm was plotted versus a range of concentrations of antibody to generate a sigmoidal curve with a "goodness of
35 fit" or correlation coefficient of 1. The absorbance was read using a Molecular

Devices plate reader (Menlo Park, Calif., USA) and Softmax (Molecular Devices Corp) software to calculate best fit by a log-logit algorithm then display the curve, equation parameters and correlation coefficient. A discussion of curve fitting appears in "Data Analysis and Quality Control of Assays: A Practical Primer", by R P Channing Rogers in Practical Immuno Assay, editor Wilfrid R Butt; published by Marcel Dekker, Inc., New York 1984. The curve fitting algorithm for the log-logit logistic equations were based on the Levenberg-Marquardt Method. Discussion of this method can be found in Numerical Principles in C: The Art of Science computing by William H Press, Brian P Flannery, Saul A Teukolski and William T Vetterling, published by Cambridge University Press, New York, 1988. The value for x in ng/ml was calculated for the following equation:

$$x = c \times \frac{[a - y]^{1/b}}{[y - d]}$$

$$\text{when } y = \frac{d - c}{2}$$

and where

d is the y-value corresponding to the asymptote at high values of the x-axis a is the y-value corresponding to the asymptote at low values of the x-axis

c is the x-value corresponding to the midpoint between a and d

b describes how rapidly the curve makes its transition from the asymptotes in the center of the curve, typically 1.

The half-maximal binding of sCD23 by chimaeric anti-CD23 was 16.28 ng/ml (See Figure 5). The half-maximal binding constant for the humanised anti-CD23 was 15.03 ng/ml (see Figure 6) This data shows that the humanised anti-CD23 has equivalent binding to the chimaeric anti-CD23 which has a complete mouse C11 variable region.

Stable Expression

Stable cell lines expressing humanised anti-CD23 were selected using the glutamine synthetase gene amplification system obtained from Celltech. The basic system described in Bebbington et al, 1992, Biotechnology 10, 169-175 was followed. This system describes making stable cell lines by introducing linearized expression vectors containing the cDNA encoding hamster glutamine synthetase under the control of the SV40 Early promoter and SV40 splicing and polyadenylation signal and the cDNA for the antibody heavy and light chain into mammalian cells by electroporation. Transfected cells are then selected for the ability to grow in glutamine free medium. NSO cells (non-immunoglobulin secreting mouse myeloma B cells) used for making the humanised anti-CD23 stable cell lines were grown in Iscove's Modified Dulbecco's Medium (Sigma) with 2 mM glutamine (GIBCO/BRL) and 10% fetal calf serum (Hyclone) (Non-Select media). The anti-CD23 cell lines were made as follows. The expression plasmid containing the humanised anti-CD23 (40 ug) was linearised with FspI (New England Biolabs), ethanol precipitated and resuspended in 50 µl of sterile water. Exponentially growing NSO cell were counted. The cells (10^7) were centrifuged and washed once in phosphate buffered saline (PBS). The cells were resuspended in 950 µl of sterile PBS. The DNA, then cells, were added to an electroporation cuvette (0.4 mm, Bio-Rad) on ice. The cuvette was placed in a Bio-Rad electroporator and two consecutive pulses at 1500 volts, 3 µF were delivered. The cuvette was removed and placed on ice. The cells were diluted to 10^4 , 10^3 , 10^2 cells/ml in Non-select media and plated in 96 well plates (Costar), 50 µl/well. The next day 150 µl of Iscove's Dulbecco's Modified Medium (Sigma) with 60 µg/ml glutamic acid (Sigma), 60 µg/ml asparagine (Sigma), 7 µg/ml each of adenosine (Sigma), guanosine (Sigma), cytidine (Sigma), uridine (Sigma), and thymidine (Sigma), and 10% fetal calf serum (Hyclone) (Select media) was added to each well. The plates were returned to a 37°C incubator and left until substantial cell death had occurred and discrete surviving colonies appeared.

Colonies were transferred from a confluent 96 well plate to one well of a 24 well plate, then after several days, the confluent well from the 24 well plate was used to inoculate a 25 cm² flask. The spent media was included with fresh Select media to perform each expansion. Once in flasks, the cultures were maintained at between 10⁵ and 10⁶ cells/ml. The specific production rate (SPR) of 144 clones was performed to compare antibody production in each clone so that the highest producing clone could be selected as a production line. The SPR was performed by taking 10⁶ cells from a confluent flask, washing the cells with PBS, then adding the cells to 10 ml of fresh media for 24 hours at 37° C. The antibody production was quantitated by ELISA.

The clones were first screened for production of human IgG using an ELISA assay as follows. EIA/RIA plates (Costar) were coated with 100 µl/well of 5 µg/ml goat anti-human IgG (Jackson Immunoresearch Labs #109-001-003) in 35 mM NaHCO₃, 15 mM Na₂CO₃, pH 9.3 overnight at 4 ° C. Plates were washed three times with 150 mM NaCl, 50 mM Trizma base, 0.1% (v/v) Tween-20, pH 7.4 (TBS/Tween), blocked for 1-2 hours at 22°C with 100 µl/well of 2% bovine serum albumin in TBS/Tween, and washed three times with TBS/Tween. One hundred microliters of control Campath-1H IgG1 [Page, M J and Sydenham (1991) (*supra*)] standard (1000 ng/ml - 1 ng/ml) in control media or sample supernatants were added, in triplicate, to wells and incubated overnight at 4° C. Plates were washed five times with TBS/Tween and 100 µl of a 1:5000 dilution of goat anti-human alkaline phosphatase conjugate (Jackson Immunoresearch Labs #109-055-088) was added and incubated for 2 hours at 22° C or overnight at 4° C. The plates were washed five times with TBS/Tween and 100 µl of 3 mM pNPP in substrate buffer (Sigma 104-0) was added and the plates read at 405 nm on a microtiter plate reader (Molecular Devices) using a 20 minute kinetic program. Standard curves and sample IgG concentrations were calculated and reported directly by the program. The SPR was expressed as µg/ 10⁶ cells/ 24 hours. The SPRs of the 144 clones ranged from 14 - 0 µg/10⁶ cells/24 hours. Clones expressing at least 5 µg / 10⁶ cells/ 24 hours were also tested for binding to sCD23 using the ELISA assay already described. Chimaeric CD23 was used as the standard for these assays.

Complement Lysis and ADCC Assays

5 FITC labelled humanised anti-CD23 was used to confirm expression of surface CD23 on RPMI 8866 cells by flow cytometry. The same cell were stained with FITC labelled humanised anti-CDw52 antibody (hCD52) and found to be negative for CD₅₂ expression. In contrast, Wein 133 cells stained positive for hCD52 but negative for anti-CD23.

10 RPMI 8866 cells were stained with europium diethylene triaminopentaacetate (Eu/DTPA) whilst Wein 133 cells were labelled with samarium diethylene triaminopentaacetate (Sm/DTPA) according to the methods described (Blomberg, K,1993, J Immunol. Methods.168,267;Patel et al, 1995.J.Immunol.Methods.184,29). A1:1 mixture of labelled Wein 133 cells and RPMI 8866 cells were then lysed with either hCD52 or anti-CD23 in the presence of NHS as a source of complement. Activation of complement through the classical pathway by hCD52 caused a release of Sm/DTPA. No Sm/DTPA was released in the presence of anti-CD23. The data confirms that only hCD52 and not anti-CD23 induces lysis of Wein 133 cells. The data further confirms that the complement pathway can be activated to cause cell lysis. No Eu/DTPA from RPMI 8866 was released by hCD52 as anticipated. Although RPMI 8866 cells express CD23, no Eu/DTPA was release by anti-CD23, demonstrating that the antibody is unable to activate complement.

25 Lysis of 1:1 mixture labelled Wein 133 and RPMI 8866 by antibody dependent cellular cytotoxicity (ADCC) was attempted with either anti-CD23 or hCD52 in the presence of peripheral blood mononuclear cells (PBMC). A release of Sm/DTPA by hCD52 and not anti-CD23 confirmed that only the latter was unable to mediate ADCC lysis of Wein 133 cells. This was not surprising, since Wein 133 cells do not express CD23. Neither of the antibodies caused a release of Eu/DTPA. This suggested that although CD23 expression was confirmed on RPMI 8866 cells by flow cytometry, no ADCC mediated cell lysis was detected with anti-CD23.

Kinetic Analysis

The association rate, dissociation rate and the dissociation rate constant for the binding of humanised anti-CD23 to the CD23 antigen was evaluated on the Biacore Biosensor. Briefly, purified recombinant CD23 was immobilised onto a CM5 sensor surface. Carboxyl groups on the dextran surface were activated by 1-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDCO/N-hydroxysuccinimide (NHS). Following activation, recombinant CD23 was passed over the surface to initiate immobilisation. Ethanolamine was then added to quench residual active groups. Humanised anti-CD23 diluted in HBS buffer was passed over the sensor surface. Binding of anti-CD23 to immobilised CD23 was monitored in real time for estimation of the association rate ($M^{-1} sec^{-1}$). Dissociation of the CD23 and the anti-CD23 complex in buffer was also monitored for estimation of the dissociation rate (sec^{-1}). The dissociation constant (nM) was calculated from the dissociation and association rate. For 6 batches of anti-CD23, the data shows association rates in the range $1.5-1.85 \times 10^6 M^{-1} sec^{-1}$ and the dissociation rate of $1 - 2 \times 10^{-5} sec^{-1}$. The dissociation constant for anti-CD23 was found to be within 8-12pM. The affinity constant was determined to be approximately $9 \times 10^{10} Ka mo^{-1}$.

CLAIMS

1. An antibody which has sufficient of the amino acid sequence of each CDR shown below such that the antibody is capable of binding to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells:
- | | |
|---------------------|-----------------------|
| RSSKSLLY KDGKTYLN | CDRL1 (SEQ ID NO: 3) |
| LMSTRAS | CDRL2 (SEQ ID NO: 5) |
| QQLVEYPFT | CDRL3 (SEQ ID NO: 7) |
| GYWMS | CDRH1 (SEQ ID NO: 9) |
| EIRLKSDNYATHYAESVKG | CDRH2 (SEQ ID NO: 11) |
| FID..... | CDRH3 (SEQ ID NO: 13) |
2. An antibody which binds to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells or soluble CD23 characterised by an affinity constant equal to or greater than 1×10^9 Ka Mo 1^{-1} .
3. An antibody which competitively inhibits the binding of an antibody having the CDR sequences set out in claim 1, to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells.
4. An antibody according to any of the preceding claims which is an altered antibody.
5. An antibody according to claim 4 which is a humanised antibody.
6. An antibody according to any of the preceding claims in which the framework of the heavy chain includes the amino acid residues from the murine antibody at any of positions 49,66,76,77 and 94.
7. An antibody according to any of the preceding claims in which the framework of the light chain included the amino acid residues from them murine antibody at position 64.

8. An antibody comprising one or both of the amino acid sequences according to SEQ ID NOS: 1 and 2.
9. An antibody comprising one or both of the amino acid sequences according to SEQ ID NOS: 17 and 18.
10. An antibody according to any of the preceding claims in which the constant region contains Ala at position 235 and Ala at position 237 by the Kabat numbering system.
11. An antibody according to any of the preceding claims for use in human therapy.
12. Use of an antibody according to any of claims 1-10 in the manufacture of a medicament for the treatment of a disorder selected from arthritis, lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, diabetes, uveitis, dermatitis, psoriasis, urticaria, nephrotic syndrome, glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Sjogren's syndrome, allergies, allergic asthma, intrinsic asthma, acute asthmatic exacerbation, rhinitis, eczema, GVH, COPD, insulinitis, bronchitis (particularly chronic bronchitis) or diabetes (particularly Type 1 diabetes), B-cell malignancies.
13. Use of an antibody which binds to the CD23 (FC ϵ RII) type II molecule expressed on haematopoietic cells in the manufacture of a medicament for blocking soluble CD23 formation.
14. Use of antibody according to claim 13 wherein the antibody is an antibody according to any one of claims 1-10.
15. A DNA sequence encoding an antibody chain which comprises one or more of the sequences according to:

CDRL1 base pair numbers 70-117 of Figure 3	(SEQ ID NOS: 4)
CDRL2 base pair numbers 163-183 of Figure 3	(SEQ ID NOS: 6)

CDRL3 base pair numbers 280-306 of Figure 3 (SEQ ID NOS: 8)

CDRH1 base pair numbers 91-105 of Figure 4 (SEQ ID NOS: 10)

CDRH2 base pair numbers 148-204 of Figure 4 (SEQ ID NOS: 12)

5 CDRH3 base pair numbers 301-309 of Figure 4 (SEQ ID NOS: 14)

16. DNA sequence encoding an antibody chain which comprises one or both
of the sequences encoding of the sequences according to SEQ ID NOS:1
and 2.

10

17. A DNA sequence encoding an antibody chain which comprises one or
both of the sequences according to SEQ ID NOS: 17 and 18

18. A pharmaceutical formulation comprising an antibody as defined in any of
the claims 1 to 10 and a pharmaceutically acceptable excipient.

15

19. A pharmaceutical formulation comprising an antibody as defined in any of
claims 1 to 10 in combination with an immunomodulatory or anti-
inflammatory agent and a pharmaceutically acceptable excipient.

20

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/13, C07K 16/28, A61K 39/395, C12N 15/62		A1	(11) International Publication Number: WO 99/58679 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/GB99/01434 (22) International Filing Date: 7 May 1999 (07.05.99) (30) Priority Data: 9809839.5 9 May 1998 (09.05.98) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BONNEFOY, Jean-Yves, Marcel, Paul [FR/FR]; Institut de Recherche Pierre Fabre, F-74164 Saint-Julien-en-Genevois Cedex (FR). CROWE, Scott, James [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). ELLIS, Jonathan, Henry [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). RAPSON, Nicholas, Timothy [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). SHEARIN, Jean [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).		(74) Agent: STOTT, Michael, J.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: ANTIBODIES TO CD23, DERIVATIVES THEREOF, AND THEIR THERAPEUTIC USES			
(57) Abstract The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterised by an affinity constant equal to or greater than $1 \times 10^9 \text{ Ka Mo}^{-1}$, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



13 Rec'd PCT/PTO 08 JUL 2002

SEQUENCE LISTING

09/674716

<110> BONNEFOY, Charles J. Ives M.P.
CROWE, James S.
ELLIS, Jonathan H.
RAPSON, Nicholas T.
SHEARIN, Jean

<120> Antibodies to CD23, derivatives thereof, and their therapeutic uses

<130> 1430-256 / PG3433USw0

<140> US 09/674,716

<141> 2001-01-22

<150> CA 2,328,606

<151> 1999-05-07

<150> PCT/GB99/01434

<151> 1999-05-07

<150> GB 9809839.5

<151> 1998-05-09

<160> 54

<170> MS Word

<210> 1

<211> 415

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (3)..(413)

<400> 1

aa gct tta cag tta ctc agc aca cag gac ctc acc atg gat ttt ggg 47
Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly
1 5 10 15

ctg att ttt ttt att gtt ctt tta aaa ggg gtc cag agt gaa gtg aag 95
Leu Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys
20 25 30

ctt gag gag tct gga gga ggc ttg gtg caa cct gga gga tcc atg aaa 143
Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys
35 40 45

ctc tcc tgt gta gcc tct gga ttt act ttc agt ggc tac tgg atg tct 191
Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser
50 55 60

tgg gtc cgc cag tct cca gag aag ggg ctt gag tgg gtt gct gaa att 239
Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile
65 70 75

aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct gtg aaa 287
 Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys
 80 85 90 95

ggg aag ttc acc atc tca aga gat gat tcc aaa agt cgt ctc tac ctg 335
 Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu
 100 105 110

caa atg aac agc tta aga gct gaa gac agt gga gtt tat tac tgt aca 383
 Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr
 115 120 125

gat ttc ata gac tgg ggc caa ggg aca cta gt 415
 Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu
 130 135

<210> 2
 <211> 437
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (3)..(437)

<400> 2

aa gct tta cag tta ctc agc aca cag gac ctc acc atg agg ttc tct 47
 Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser
 1 5 10 15

gtt cag ttt ctg ggg gtg ctt atg ttc tgg atc tct gga gtc agt ggg 95
 Val Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly
 20 25 30

gat att gtg ata acc cag gat gaa ctc tcc aat cct gtc act tct gga 143
 Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly
 35 40 45

gaa tca gtt tcc atc tcc tgc agg tct agt aag agt ctc ctg tat aag 191
 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
 50 55 60

gat ggg aag aca tac ttg aat tgg ttt ctg cag aga cca gga caa tct 239
 Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
 65 70 75

cct cag ctc ctg atg tat ttg atg tcc acc cgt gca tca gga gtc tca 287
 Pro Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser
 80 85 90 95

gac cgg ttt agt ggc agt ggg tca ggc aca gat ttc acc ctg gaa atc 335
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile
 100 105 110

agt aga gtg aag gct gag gat gtg ggt gtg tat tac tgt caa caa ctt 383

Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
115 120 125

gta gag tat cca ttc acg ttc ggc tgc ggg aca aag ttg gaa ata aaa 431
Val Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
130 135 140

cgt acg 437
Arg Thr
145

<210> 3
<211> 16
<212> PRT
<213> Mus musculus

<400> 3
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
1 5 10 15

<210> 4
<211> 48
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(48)

<400> 4
cgc tgc agt aag agt ctc ctg tat aag gat ggc aag aca tac ttg aat 48
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
1 5 10 15

<210> 5
<211> 7
<212> PRT
<213> Mus musculus

<400> 5
Leu Met Ser Thr Arg Ala Ser
1 5

<210> 6
<211> 21
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(21)

<400> 6
ttg atg tcc acc cgg gca tca 21
Leu Met Ser Thr Arg Ala Ser
1 5

$$\frac{d}{dt} \left(\frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}, \quad \frac{d}{dt} \left(\frac{\partial L}{\partial \dot{y}} \right) = \frac{\partial L}{\partial y}, \quad \frac{d}{dt} \left(\frac{\partial L}{\partial \dot{z}} \right) = \frac{\partial L}{\partial z}$$

```
<210> 8
<211> 27
<212> DNA
<213> Mus musculus
```

```
<400> 8
caa cag ctg gta gag tat cca ttc acg
Gln Gln Leu Val Glu Tyr Pro Phe Thr
      1                5
```

27

```
<400> 9
Gly Tyr Trp Met Ser
  1                      5
```

```
<220>
<221> CDS
<222> (1) .. (15)
```

```
<400> 10
ggc tac tgg atg tcc
Gly Tyr Trp Met Ser
      1                      5
```

15

<400> 11
Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser
1 5 10 15

Val Lys Gly

<210> 12
 <211> 57
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(57)

<400> 12
 gaa att aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct 48
 Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser
 1 5 10 15
 gtg aag ggg 57
 Val Lys Gly

<210> 13
 <211> 3
 <212> PRT
 <213> Mus musculus

<400> 13
 Phe Ile Asp
 1

<210> 14
 <211> 9
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(9)

<400> 14
 ttc ata gac 9
 Phe Ile Asp
 1

<210> 15
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic sequence

<400> 15
 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15
 Val His Ser

<210> 16

<211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic sequence

<400> 16
 Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser
 1 5 10 15

Ala Gln Ala

<210> 17
 <211> 348
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Humanised anti-CD23 antibody VL region

<220>
 <221> CDS
 <222> (1)..(348)

<400> 17
 gat att gtg atg act cag tct cca ctc tcc ctg ccc gtc acc cct gga 48
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15

gag ccg gcc tcc atc tcc tgt cgc tcg agt aag agt ctc ctg tat aag 96
 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
 20 25 30

gat ggg aag aca tac ttg aat tgg tac ctg cag aag cca ggg cag tct 144
 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

cca cag ctc ctg atc tat ttg atg tcc acc cgg gca tca ggg gtc cct 192
 Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
 50 55 60

gac agg ttc agt ggc agt gga tca ggc aca gat ttt aca ctg aaa atc 240
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

agc aga gtg gag gct gag gat gtt ggg gtt tat tac tgt caa cag ctg 288
 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
 85 90 95

gta gag tat cca ttc acg ttc ggc caa ggg acc aag gtg gag atc aaa 336
 Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

cgt acg gtg gct 348

Arg Thr Val Ala
115

<210> 18

<211> 1335

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody VH region

<220>

<221> CDS

<222> (1)..(1335)

<400> 18

gag	gtg	cag	ctg	gtg	gag	tct	ggg	gga	ggc	ttg	gta	aag	ccc	ggg	ggg	48
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly	
1				5					10					15		
tcc	ctt	aga	ctc	tcc	tgt	gca	gct	agc	gga	ttc	act	ttc	agt	ggc	tac	96
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	
			20					25					30			
tgg	atg	tcc	tgg	gtc	cgc	cag	gct	cca	ggg	aag	ggg	ctc	gag	tgg	gtt	144
Trp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35				40						45				
gct	gaa	att	aga	ttg	aaa	tct	gat	aat	tat	gca	aca	cat	tat	gcg	gag	192
Ala	Glu	Ile	Arg	Leu	Lys	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	
	50					55					60					
tct	gtg	aag	ggg	aaa	ttc	acc	atc	tca	aga	gat	gat	tca	aaa	tct	aga	240
Ser	Val	Lys	Gly	Lys	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Arg	
65					70				75				80			
ctg	tat	ctg	caa	atg	aac	agc	ctg	aaa	acc	gag	gac	aca	gcc	gtg	tat	288
Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Val	Tyr	
			85					90					95			
tac	tgt	aca	gat	ttc	ata	gac	tgg	ggc	cag	gga	aca	cta	gtc	acc	gtc	336
Tyr	Cys	Thr	Asp	Phe	Ile	Asp	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	
			100					105					110			
tcc	tca	gcc	tcc	acc	aag	ggc	cca	tcg	gtc	ttc	ccc	ctg	gca	ccc	tcc	384
Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	
		115					120					125				
tcc	aag	agc	acc	tct	ggg	ggc	aca	gcg	gcc	ctg	ggc	tgc	ctg	gtc	aag	432
Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	
	130					135					140					
gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg	tcg	tgg	aac	tca	ggc	gcc	ctg	480
Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	
145					150					155					160	

acc agc ggc gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc	528
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu	
165 170 175	
tac tcc ctc agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc	576
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr	
180 185 190	
cag acc tac atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg	624
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val	
195 200 205	
gac aag aaa gtg gag ccc aaa tct tgt gac aaa act cac aca tgc cca	672
Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro	
210 215 220	
ccg tgc cca gca cct gaa ctc gcg ggg gca ccg tca gtc ttc ctc ttc	720
Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu Phe	
225 230 235 240	
ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc	768
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val	
245 250 255	
aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc	816
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe	
260 265 270	
aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg	864
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro	
275 280 285	
cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc	912
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr	
290 295 300	
gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc	960
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val	
305 310 315 320	
tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc	1008
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala	
325 330 335	
aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc ccg	1056
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg	
340 345 350	
gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc	1104
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly	
355 360 365	
ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg	1152
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro	
370 375 380	
gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc	1200

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 385 390 395 400
 ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag 1248
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 405 410 415
 ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac 1296
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 420 425 430
 tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1335
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 435 440

<210> 19
 <211> 57
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 19
 gatgaagctt tacagttact cagcacacag gacctcacca tggattttgg gctgatt 57

<210> 20
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 20
 gatggactag tgtcccttgg cccca 25

<210> 21
 <211> 57
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 21
 gatgaagctt tacagttact cagcacacag gacctcacca tgaggttctc tgttcag 57

<210> 22
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 22

gatgcgtacg tytkatytcc avcttkgt

28

<210> 23
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide

<400> 23
gatcaagctt ctctacagtt actgagcaca

30

<210> 24
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide

<400> 24
aatcaagtat gtcttcccat ccttatacag gagactotta ctcgagcgac aggagatgga 60
ggc 63

<210> 25
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide

<400> 25
cgctcgagta agagtctcct gtataaggat gggaagacat acttgaattg gtacctgcag 60
aag 63

<210> 26
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide

<400> 26
tgatgcccgg gtggacatca aatagatcag gagctg

36

<210> 27
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide

<400> 27

ttgatgtcca ccggggcac aggggtccct gacagg

36

<210> 28

<211> 84

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 28

agccaccta cgtttgatct ccaccttggg cccttggcgg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa cccc 84

<210> 29

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 29

acacgaagct tcacatggc ttgggtgtgg accttgctat tctgatggc ggccgcccac 60

<210> 30

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 30

ctttaccaag cctccccag actccaccag ctgcacctct gcttgggcac tttgggcggc 60
cgccat 66

<210> 31

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 31

ttggtaaagc ccgggggggc ccttagactc tctgtgcag ctagcggatt cactttcagt 60

<210> 32

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 32

$$\frac{1}{2} \cdot \frac{1}{2} = \frac{1}{4}, \quad \frac{1}{4} \cdot \frac{1}{4} = \frac{1}{16}, \quad \frac{1}{16} \cdot \frac{1}{16} = \frac{1}{256}, \quad \dots$$

<213> Artificial Sequence

<223> Description of Artificial Sequence: Oligonucleotide

gggaaggggc tcgagtgggt tgctgaaatt agattgaaat ctgataatta tgcaacacat 60

<213> Artificial Sequence

<223> Description of Artificial Sequence: Oligonucleotide

atcatctctt gagatggtga atttcccctt cacagactcc gcataatgtg ttgcataatt 60

<213> Artificial Sequence

<223> Description of Artificial Sequence: Oligonucleotide

atctcaagag atgattcaaa atctagactg tatctgcaaa tgaacagcct gaaaaccgag 60
gacaca 66

<213> Artificial Sequence

<223> Description of Artificial Sequence: Oligonucleotide

```

gtgtgactagt gttccctggc cccagttctat gaaatctgta cagtaataca cggtctgtgtc 60
ctcgggtttt                                     69

```

<213> Artificial Sequence

<223> Description of Artificial Sequence: Oligonucleotide

<400> 37

gctgctcctt ttaagctttg gggccaaggc tcactagtca cagtctcc

48

<210> 38

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 38

tgacggtgcc cccgcgagtt cagg

24

<210> 39

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 39

cctgaactcg cgggggcacc gtca

24

<210> 40

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide

<400> 40

aagcttccgt cgaattcatt taccggaga cag

33

<210> 41

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 41

actagtcgac atgaagtttc cttctcaact tctgctc

37

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 42

Thr Lys Leu Glu Ile Lys Arg Thr
1 5

<210> 43
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 43
Thr Lys Val Glu Ile Lys Arg Thr
1 5

<210> 44
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 44
Thr Lys Leu Glu Ile Arg Arg Thr
1 5

<210> 45
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic sequence

<400> 45
Thr Lys Val Glu Ile Arg Arg Thr
1 5

<210> 46
<211> 415
<212> DNA
<213> Mus musculus

<400> 46
actagtgtcc cttggcccca gtctatgaaa tctgtacagt aataaaactcc actgtcttca 60
gctcttaagc tgttcatttg caggtagaga cgacttttgg aatcatctct tgagatgggtg 120
aacttccctt tcacagactc cgcataatgt gttgcataat tatcagattt caatctaatt 180
tcagcaaccc actcaagccc cttctctgga gactggcgga cccaagacat ccagtagcca 240
ctgaaagtaa atccagaggc tacacaggag agtttcatgg atcctccagg ttgcaccaag 300
cctcctccag actcctcaag cttcacttca ctctggaccc cttttaaaaag aacaataaaa 360
aaaatcagcc caaaatccat ggtgaggtcc tgtgtgctga gtaactgtaa agctt 415

<210> 47
<211> 437
<212> DNA
<213> Mus musculus

```

<400> 47
cgtagctttt atttccaact ttgtccccga gccgaacgtg aatggatact ctacaagttg 60
ttgacagtaa tacacaccca catcctcagc cttcactcta ctgatttcca gggtgaaatc 120
tgtgcctgac ccactgccac taaaccggtc tgagactcct gatgcacggg tggacatcaa 180
atacatcagg agctgaggag attgtcctgg tctctgcaga aaccaattca agtatgtcct 240
ccatccttta tacaggagac tottactaga cctgcaggag atggaaactg attctccaga 300
agtgcacagga ttggagagtt catcctgggt tatcacaata tccccactga ctccagagat 360
ccagaacata agcaccacca gaaactgaac agagaacctc atggtgaggt cctgtgtgct 420
gagtaactgt aaagctt                                     437

<210> 48
<211> 348
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Humanised anti-CD23 antibody VL
region

<400> 48
agccaccgta cgtttgatct ccaccttggg ccttggccg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa ccccaacatc ctcagcctcc actctgctga ttttcagtgt 120
aaaatctgtg cctgatccac tgccactgaa cctgtcaggg acccctgatg cccgggtgga 180
catcaaatag atcaggagct gtggagactg ccttggtctt tgcaggatcc aattcaagta 240
tgtcttccca tccttatata ggagactctt actcgagcga caggagatgg aggccggctc 300
tcagggggtg acgggcaggg agagtggaga ctgagtcac acaatate                                     348

<210> 49
<211> 1335
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Humanised anti-CD23 antibody VH
region

<400> 49
tcatttaccg ggagacaggg agaggctctt ctgcgtgtag tggttgtgca gaggctcatg 60
catcacggag catgagaaga cgttcccttg ctgccacctg ctcttgcca cggtagactt 120
gctgtagagg aagaaggagc cgtcggagtc cagcacggga ggcgtggtct tgtagtgtgt 180
ctccggctgc ccattgctct cccactccac ggcatgtctg ctgggataga agcctttgac 240
caggcaggtc aggtgacct ggttcttggg cagctcatcc cgggatgggg gcagggtgta 300
cacctgtggt tctcggggct gccctttggc ttlgagatg gttttctcga tggggctgg 360
gagggctttg ttggagacct tgcacttgta ctcttgcca ttcagccagt cctggtgcag 420
gacggtgagg acgctgacca cacggtaagt gctgtgttac tgcctctccc gcggctttgt 480
cttggcatta tgcacctcca cgcgctccac gtaccagttg aacttgacct cagggtcttc 540
gtggtcacg tccaccacca cgcattgtgac ctcagggttc cgggagatca tgagggtgtc 600
cttgggtttt ggggggaaga ggaagactga cgggtccccc gcgagttcag gtgctgggca 660
cgggtgggcat gtgtgagttt tgtcacaaga tttgggtccc actttcttgt ccaccttggg 720
gttctggggc ttgtgattca cgttgcatg tttaggtctg gtgcccagc tgcaggagg 780
caggtgtcac acgctgctga gggagtagag tcttaggac tgtaggacag cggggaaggt 840
gtgcaacgag ctggtcaggg cgcctgagtt ccacgacacc gtcaccggtt cggggaagta 900
gtccttgacc aggcagccca gggccgctgt gccccagag gtgctcttgg aggaggggtc 960
cagggggaag accgatgggc ccttggtgga ggctgaggag acggtgacta gtgttccctg 1020
gccccagttc atgaaatctg tacagtaata cacggtgtgt tctcgggtt tcaggctgtt 1080
catttgcaga tacagtctag attttgaate atctcttgag atggtgaatt tccccctcac 1140

```

agactccgca taatgtgttg cataattatc agattttcaat ctaatttcag caaccctc 1200
gagcccttc cctggagcct ggcggaccca ggacatccag tagccactga aagtgaatcc 1260
gctagctgca caggagagtc taagggaccc cccgggcttt accaagctc cccagactc 1320
caccagctgc acctc 1335

<210> 50
<211> 137
<212> PRT
<213> Mus musculus

<400> 50
Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly Leu
1 5 10 15
Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys Leu
20 25 30
Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu
35 40 45
Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser Trp
50 55 60
Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg
65 70 75 80
Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly
85 90 95
Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu Gln
100 105 110
Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr Asp
115 120 125
Phe Ile Asp Trp Gly Gln Gly Thr Leu
130 135

<210> 51
<211> 145
<212> PRT
<213> Mus musculus

<400> 51
Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser Val
1 5 10 15
Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly Asp
20 25 30
Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly Glu
35 40 45
Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp
50 55 60

Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro
65 70 75 80

Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser Asp
85 90 95

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser
100 105 110

Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu Val
115 120 125

Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg
130 135 140

Thr
145

<210> 52
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Humanised anti-CD23 antibody VL
region

<400> 52
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
20 25 30

Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
85 90 95

Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

Arg Thr Val Ala
115

<210> 53
<211> 444
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody VH region

<400> 53

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110

Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
115 120 125

Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
130 135 140

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
145 150 155 160

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
165 170 175

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
180 185 190

Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
195 200 205

Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
210 215 220

Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu Phe
225 230 235 240

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
260 265 270

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
340 345 350

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
405 410 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

<210> 54

<211> 8

<212> PRT

<213> Homo sapiens

<400> 54

His Ser Ile Gly Lys Val Ile Ile

1

5

SEQUENCE LISTING

<110> Glaxo Group Limited.
Bonnefoy, Jean-Yves
Ellis, Jonathan H

<120> Antibody.

<130> PG3433

<140>

<141>

<150> GB 9809839.5

<151> 1998-05-09

<160> 53

<170> PatentIn Ver. 2.1

<210> 1

<211> 415

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (3)..(413)

<400> 1

aa gct tta cag tta ctc agc aca cag gac ctc acc atg gat ttt ggg 47
Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly
1 5 10 15

ctg att ttt ttt att gtt ctt tta aaa ggg gtc cag agt gaa gtg aag 95
Leu Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys
20 25 30

WO 99/58679

PCT/GB99/01434

2

ctt gag gag tct gga gga ggc ttg gtg caa cct gga gga tcc atg aaa 143
Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys

35

40

45

ctc tcc tgt gta gcc tct gga ttt act ttc agt ggc tac tgg atg tct 191
Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser

50

55

60

tgg gtc cgc cag tct cca gag aag ggg ctt gag tgg gtt gct gaa att 239
Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile

65

70

75

aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct gtg aaa 287
Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys

80

85

90

95

ggg aag ttc acc atc tca aga gat gat tcc aaa agt cgt ctc tac ctg 335
Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu

100

105

110

caa atg aac agc tta aga gct gaa gac agt gga gtt tat tac tgt aca 383
Gln Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr

115

120

125

gat ttc ata gac tgg ggc caa ggg aca cta gt 415
Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu

130

135

<210> 2

<211> 437

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (3)..(437)

WO 99/58679

PCT/GB99/01434

3

<400> 2

```

aa gct tta cag tta ctc agc aca cag gac ctc acc atg agg ttc tct      47
  Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser
    1             5             10             15

gtt cag ttt ctg ggg gtg ctt atg ttc tgg atc tct gga gtc agt ggg      95
Val Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly
          20             25             30

gat att gtg ata acc cag gat gaa ctc tcc aat cct gtc act tct gga     143
Asp Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly
          35             40             45

gaa tca gtt tcc atc tcc tgc agg tct agt aag agt ctc ctg tat aag     191
Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
          50             55             60

gat ggg aag aca tac ttg aat tgg ttt ctg cag aga cca gga caa tct     239
Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser
          65             70             75

cct cag ctc ctg atg tat ttg atg tcc acc cgt gca tca gga gtc tca     287
Pro Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser
          80             85             90             95

gac cgg ttt agt ggc agt ggg tca ggc aca gat ttc acc ctg gaa atc     335
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile
          100            105            110

agt aga gtg aag gct gag gat gtg ggt gtg tat tac tgt caa caa ctt     383
Ser Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
          115            120            125

gta gag tat cca ttc acg ttc ggc tcg ggg aca aag ttg gaa ata aaa     431
Val Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
          130            135            140

```

cgt acg

437

Arg Thr

145

<210> 3

<211> 16

<212> PRT

<213> Mus musculus

<400> 3

Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn

1

5

10

15

<210> 4

<211> 48

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(48)

<400> 4

cgc tcg agt aag agt ctc ctg tat aag gat ggg aag aca tac ttg aat 48

Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn

1

5

10

15

<210> 5

<211> 7

<212> PRT

<213> Mus musculus

<400> 5

Leu Met Ser Thr Arg Ala Ser

1

5

<210> 6
<211> 21
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(21)

<400> 6
ttg atg tcc acc cgg gca tca
Leu Met Ser Thr Arg Ala Ser
1 5

21

<210> 7
<211> 9
<212> PRT
<213> Mus musculus

<400> 7
Gln Gln Leu Val Glu Tyr Pro Phe Thr
1 5

<210> 8
<211> 27
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (1)..(27)

<400> 8
caa cag ctg gta gag tat cca ttc acg
Gln Gln Leu Val Glu Tyr Pro Phe Thr
1 5

27

<210> 9

<211> 5

<212> PRT

<213> Mus musculus

<400> 9

Gly Tyr Trp Met Ser

1 5

<210> 10

<211> 15

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(15)

<400> 10

ggc tac tgg atg tcc

15

Gly Tyr Trp Met Ser

1 5

<210> 11

<211> 19

<212> PRT

<213> Mus musculus

<400> 11

Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser

1 5 10 15

Val Lys Gly

<210> 12

<211> 57

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(57)

<400> 12

gaa att aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct 48
Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser
1 5 10 15

gtg aag ggg

57

Val Lys Gly

<210> 13

<400> 13

000

<210> 14

<400> 14

000

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 15

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser

<210> 16

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 16

Met	Ala	Trp	Val	Trp	Thr	Leu	Leu	Phe	Leu	Met	Ala	Ala	Ala	Gln	Ser
1				5					10					15	

Ala Gln Ala

<210> 17

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
anti-CD23 antibody light chain variable region

<220>

<221> CDS

<222> (1)..(348)

<400> 17

gat	att	gtg	atg	act	cag	tct	cca	ctc	tcc	ctg	ccc	gtc	acc	cct	gga	48
Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Leu	Ser	Leu	Pro	Val	Thr	Pro	Gly	
1				5					10					15		

gag ccg gcc tcc atc tcc tgt cgc tgc agt aag agt ctc ctg tat aag	96
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys	
20 25 30	
gat ggg aag aca tac ttg aat tgg tac ctg cag aag cca ggg cag tct	144
Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
cca cag ctc ctg atc tat ttg atg tcc acc cgg gca tca ggg gtc cct	192
Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro	
50 55 60	
gac agg ttc agt ggc agt gga tca ggc aca gat ttt aca ctg aaa atc	240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile	
65 70 75 80	
agc aga gtg gag gct gag gat gtt ggg gtt tat tac tgt caa cag ctg	288
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu	
85 90 95	
gta gag tat cca ttc acg ttc ggc caa ggg acc aag gtg gag atc aaa	336
Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys	
100 105 110	
cgt acg gtg gct	348
Arg Thr Val Ala	
115	

<210> 18

<211> 1335

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised

anti-CD23 antibody heavy chain variable region.

10

<220>

<221> CDS

<222> (1)..(1335)

<400> 18

gag	gtg	cag	ctg	gtg	gag	tct	ggg	gga	ggc	ttg	gta	aag	ccc	ggg	ggg	48
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly	
1				5						10					15	
tcc	ctt	aga	ctc	tcc	tgt	gca	gct	agc	gga	ttc	act	ttc	agt	ggc	tac	96
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	
			20					25					30			
tgg	atg	tcc	tgg	gtc	cgc	cag	gct	cca	ggg	aag	ggg	ctc	gag	tgg	gtt	144
Trp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35				40						45				
gct	gaa	att	aga	ttg	aaa	tct	gat	aat	tat	gca	aca	cat	tat	gcg	gag	192
Ala	Glu	Ile	Arg	Leu	Lys	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	
		50				55						60				
tct	gtg	aag	ggg	aaa	ttc	acc	atc	tca	aga	gat	gat	tca	aaa	tct	aga	240
Ser	Val	Lys	Gly	Lys	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Arg	
65					70					75				80		
ctg	tat	ctg	caa	atg	aac	agc	ctg	aaa	acc	gag	gac	aca	gcc	gtg	tat	288
Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Val	Tyr	
				85					90					95		
tac	tgt	aca	gat	ttc	ata	gac	tgg	ggc	cag	gga	aca	cta	gtc	acc	gtc	336
Tyr	Cys	Thr	Asp	Phe	Ile	Asp	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	
			100					105					110			
tcc	tca	gcc	tcc	acc	aag	ggc	cca	tcg	gtc	ttc	ccc	ctg	gca	ccc	tcc	384
Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	
		115					120					125				

WO 99/58679

PCT/GB99/01434

11

tcc aag agc acc tct ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag	432
Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys	
130 135 140	
gac tac ttc ccc gaa ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg	480
Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu	
145 150 155 160	
acc agc ggc gtg cac acc ttc ccg gct gtc cta cag tcc tca gga ctc	528
Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu	
165 170 175	
tac tcc ctc agc agc gtg gtg acc gtg ccc tcc agc agc ttg ggc acc	576
Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr	
180 185 190	
cag acc tac atc tgc aac gtg aat cac aag ccc agc aac acc aag gtg	624
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val	
195 200 205	
gac aag aaa gtg gag ccc aaa tct tgt gac aaa act cac aca tgc cca	672
Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro	
210 215 220	
ccg tgc cca gca cct gaa ctc gcg ggg gca ccg tca gtc ttc ctc ttc	720
Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu Phe	
225 230 235 240	
ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc	768
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val	
245 250 255	
aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc	816
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe	
260 265 270	

aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg 864
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 275 280 285

cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc 912
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 290 295 300

gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc 960
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 305 310 315 320

tcc aac aaa gcc ctc cca gcc ccc atc gag aaa acc atc tcc aaa gcc 1008
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
 325 330 335

aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg 1056
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 340 345 350

gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc 1104
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 355 360 365

ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg 1152
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 370 375 380

gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc 1200
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 385 390 395 400

ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag 1248
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 405 410 415

13

ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac 1296
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430

tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1335
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

<210> 19

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 19

gatgaagctt tacagttact cagcacacag gacctcacca tggatttttg gctgatt 57

<210> 20

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 20

gatggactag tgtcccttgg cccca 25

<210> 21

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 21

gatgaagctt tacagttact cagcacacag gacctcacca tgaggttctc tgttcag 57

<210> 22

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 22

gatgcgtacg tytkatytcc avcttkgt 28

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 23

gatcaagctt ctctacagtt actgagcaca 30

<210> 24

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 24

aatcaagtat gtcttcccat ccttatacag gagactctta ctcgagcgcac aggagatgga 60
ggc 63

<210> 25

<211> 63

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 25

cgctcgagta agagtctcct gtataaggat gggaagacat acttgaattg gtacctgcag 60
aag 63

<210> 26

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 26

tgatgcccgg gtggacatca aatagatcag gagctg 36

<210> 27

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 27

ttgatgtcca cccgggcac aggggtccct gacagg 36

<210> 28

<211> 84

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 28

agccacctga cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa cccc 84

<210> 29

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 29

acacgaagct tcaccatggc ttgggtgtgg accttgctat tcctgatggc ggccgccc aa 60

<210> 30

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 30

ctttaccaag cctccccag actccaccag ctgcacctct gcttgggcac tttgggcggc 60
cgccat 66

<210> 31

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 31

ttggtaaagc ccgggggggtc ccttagactc tcctgtgcag ctagcggatt cactttcagt 60

<210> 32

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 32

ccccttcctt ggagcctggc ggacccagga catccagtag ccactgaaag tgaatccgct 60

<210> 33

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 33

gggaaggggc tcgagtgggt tgctgaaatt agattgaaat ctgataatta tgcaacacat 60

<210> 34

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 34

atcatctctt gagatgggtga atttcccctt cacagactcc gcataatgtg ttgcataatt 60

<210> 35

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 35

atctcaagag atgattcaaa atctagactg tatctgcaaa tgaacagcct gaaaaccgag 60
gacaca 66

<210> 36

<211> 69

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 36

ggtgactagt gttccctggc cccagtctat gaaatctgta cagtaataca cggctgtgtc 60
ctcggtttt 69

<210> 37

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 37

gctgctcctt ttaagctttg gggtaagggc tcactagtca cagtctcc 48

WO 99/58679

PCT/GB99/01434

19

<210> 38

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 38

tgacggtgcc cccgcgagtt cagg

24

<210> 39

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 39

cctgaactcg cgggggcacc gtca

24

<210> 40

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo

<400> 40

aagcttccgt cgaattcatt taccggaga cag

33

<210> 41

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 41

actagtcgac atgaagtttc cttctcaact tctgctc

37

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 42

Thr Lys Leu Glu Ile Lys Arg Thr

1

5

<210> 43

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 43

Thr Lys Val Glu Ile Lys Arg Thr

1

5

<210> 44

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 44

Thr Lys Leu Glu Ile Arg Arg Thr

1

5

<210> 45

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 45

Thr Lys Val Glu Ile Arg Arg Thr

1

5

<210> 46

<211> 415

<212> DNA

<213> Mus musculus

<400> 46

```
actagtgtcc cttggcecca gtctatgaaa tctgtacagt aataaactcc actgtcttca 60
gctcttaagc tgttcatttg caggtagaga cgacttttgg aatcatctct tgagatgggtg 120
aacttccctt tcacagactc cgcataatgt gttgcataat tatcagattt caatctaatt 180
tcagcaaccc actcaagccc cttctctgga gactggcgga cccaagacat ccagtagcca 240
ctgaaagtaa atccagaggc tacacaggag agtttcatgg atcctccagg ttgcaccaag 300
ctcctccag actcctcaag cttcacttca ctctggaccc cttttaaaag aacaataaaa 360
aaaatcagcc caaaatccat ggtgagggtcc tgtgtgctga gtaactgtaa agctt 415
```

<210> 47

<211> 437

<212> DNA

<213> Mus musculus

<400> 47

```
cgtacgtttt atttccaact ttgtccccga gccgaacgtg aatggatact ctacaagttg 60
ttgacagtaa tacacaccca catcctcagc cttcactcta ctgatttcca gggtgaaatc 120
tgtgcctgac ccactgccac taaaccggtc tgagactcct gatgcacggg tggacatcaa 180
atacatcagg agctgaggag attgtcctgg tctctgcaga aaccaattca agtatgtcct 240
cccatcctta tacaggagac tcttactaga cctgcaggag atggaaactg attctccaga 300
agtgcagga ttggagagtt catcctgggt tatcacaata tccccactga ctccagagat 360
ccagaacata agcaccacca gaaactgaac agagaacctc atggtgaggt cctgtgtgct 420
gagtaactgt aaagctt                                     437
```

<210> 48

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
anti-CD23 antibody light chain variable region

<400> 48

```
agccaccgta cgtttgatct ccaccttggc cccttggccg aacgtgaatg gatactctac 60
cagctgttga cagtaataaa cccaacatc ctcagcctcc actctgctga ttttcagtgt 120
aaaatctgtg cctgatccac tgccactgaa cctgtcaggg acccctgatg cccgggtgga 180
catcaaatag atcaggagct gtggagactg ccctggcttc tgcaggtacc aattcaagta 240
tgtcttccca tccttataca ggagactctt actcgagcga caggagatgg aggccggctc 300
tccaggggtg acgggcaggg agagtggaga ctgagtcac acaatatac                                     348
```

<210> 49

<211> 1335

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
anti-CD23 antibody heavy chain variable region

<400> 49

```

tcatttaccc ggagacaggg agaggctctt ctgcgtgtag tggttgtgca gagcctcatg 60
catcacggag catgagaaga cgttcccctg ctgccacctg ctcttgcca cggtgagctt 120
gctgtagagg aagaaggagc cgtcggagtc cagcacggga ggcgtggtct tgtagttgtt 180
ctccggctgc ccattgctct cccactccac ggcgatgtcg ctgggataga agcctttgac 240
caggcaggtc aggttgacct ggttcttggt cagctcatcc cgggatgggg gcagggtgta 300
cacctgtggt tctcggggct gccctttggc tttggagatg gttttctcga tgggggctgg 360
gagggctttg ttggagacct tgcacttgta ctcttgcca ttcagccagt cctggtgcag 420
gacggtgagg acgtgacca caggtacgt gctgtgttac tgctcctccc gcggtttgt 480
cttggcatta tgcacctcca cgcgtccac gtaccagttg aacttgacct cagggctctc 540
gtggctcacg tccaccacca cgcagtgtac ctgaggggtc cgggagatca tgagggtgtc 600
cttgggtttt ggggggaaga ggaagactga cggtgcccc gcgagttcag gtgctgggca 660
cgggtggcat gtgtgagttt tgtcacaaga tttgggtcc actttcttgt ccaccttgg 720
gttctggggc ttgtgattca cgttgcatat gtaggtctgg gtgcccagc tgctggaggg 780
cacggtcacc acgtgctga gggagtagag tcctgaggac tgtaggacag ccgggaaggt 840
gtgcacgccg ctggtcaggg cgcctgagtt ccacgacacc gtcaccggtt cggggaagta 900
gtccttgacc aggcagccca gggccgctgt gccccagag gtgctcttgg aggaggggtc 960
cagggggaag accgatgggc ccttggtgga ggctgaggag acggtgacta gtgttccctg 1020
gccccagtct atgaaatctg tacagtaata cagggctgtg tcctcggttt tcaggctgtt 1080
catttgacaga tacagtctag attttgaatc atctcttgag atggtgaatt tccccctcac 1140
agaactccga taatgtgttg cataattatc agatttcaat ctaatttcag caaccctc 1200
gagccccctc cctggagcct ggcggacca ggacatccag tagccactga aagtgaatcc 1260
gctagctgca caggagagtc taagggaccc cccgggcttt accaagcctc cccagactc 1320
caccagctgc acctc 1335

```

<210> 50

<211> 137

<212> PRT

<213> Mus musculus

<400> 50

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly Leu

1

5

10

15

24

Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys Leu
20 25 30

Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu
35 40 45

Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser Trp
50 55 60

Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg
65 70 75 80

Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly
85 90 95

Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu Gln
100 105 110

Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr Asp
115 120 125

Phe Ile Asp Trp Gly Gln Gly Thr Leu
130 135

<210> 51

<211> 145

<212> PRT

<213> Mus musculus

<400> 51

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser Val
1 5 10 15

Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly Asp
20 25 30

Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly Glu
35 40 45

25

Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp
50 55 60

Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro
65 70 75 80

Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser Asp
85 90 95

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser
100 105 110

Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu Val
115 120 125

Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg
130 135 140

Thr

145

<210> 52

<211> 116

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised
anti-CD23 antibody light chain variable region

<400> 52

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys
20 25 30

Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

26

Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu
85 90 95

Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

Arg Thr Val Ala
115

<210> 53

<211> 444

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised
anti-CD23 antibody heavy chain variable region.

<400> 53

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg
65 70 75 80

27

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Thr Asp Phe Ile Asp Trp Gly Gln Gly Thr Leu Val Thr Val
 100 105 110

Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser
 115 120 125

Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
 130 135 140

Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
 145 150 155 160

Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu
 165 170 175

Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
 180 185 190

Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
 195 200 205

Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
 210 215 220

Pro Cys Pro Ala Pro Glu Leu Ala Gly Ala Pro Ser Val Phe Leu Phe
 225 230 235 240

Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 245 250 255

Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 260 265 270

Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 275 280 285

28

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
340 345 350

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
405 410 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440

1/6

1 AAGCTTTACAGTTACTCAGCACACAGGACCTCACCATGGATTTTGGGCTGATTTTTTTTA 60
-----+-----+-----+-----+-----+-----+
TTCGAAATGTCAATGAGTCGTGTGTCCTGGAGTGGTACCTAAAACCCGACTAAAAAAAT
C A L Q L L S T Q D L T M D F G L I F F I -
61 TTGTTCTTTTAAAAGGGGTCCAGAGTGAAGTGAAGCTTGAGGAGTCTGGAGGAGGCTTGG 120
-----+-----+-----+-----+-----+-----+
AACAAGAAAATTTCCCCAGGTCTCACTTCACTTCGAACTCCTCAGACCTCCTCCGAACC
C V L L K G V Q S E V K L E E S G G G L V -
121 TGCAACCTGGAGGATCCATGAACTCTCCTGTGTAGCCTCTGGATTTACTTTTCAGTGGCT 180
-----+-----+-----+-----+-----+-----+
ACGTTGGACCTCCTAGGTACTTTGAGAGGACACATCGGAGACCTAAATGAAAGTCACCGA
C Q P G G S M K L S C V A S G F T F S G Y -
181 ACTGGATGTCTTGGGTCCGCCAGTCTCCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTA 240
-----+-----+-----+-----+-----+-----+
TGACCTACAGAACCCAGGCGGTGAGAGGTCTCTTCCCCGAACTCACCCAACGACTTTAAT
C W M S W V R Q S P E K G L E W V A E I R -
241 GATTGAAATCTGATAATTATGCAACACATTATGCGGAGTCTGTGAAAGGGAAGTTCACCA 300
-----+-----+-----+-----+-----+-----+
CTAACTTTAGACTATTAATACGTTGTGTAATACGCCTCAGACACTTTCCCTTCAAGTGGT
C L K S D N Y A T H Y A E S V K G K F T I -
301 TCTCAAGAGATGATTCCAAAAGTCGTCTCTACCTGCAAATGAACAGCTTAAGAGCTGAAG 360
-----+-----+-----+-----+-----+-----+
AGAGTTCTCTACTAAGGTTTTTCAGCAGAGATGGACGTTTACTTGTCGAATTCTCGACTTC
C S R D D S K S R L Y L Q M N S L R A E D -
361 ACAGTGGAGTTTATTACTGTACAGATTTTCATAGACTGGGGCCAAGGGACACTAGT 415
-----+-----+-----+-----+-----+-----+
TGTCACCTCAAATAATGACATGTCTAAAGTATCTGACCCCGGTTCCCTGTGATCA
C S G V Y Y C T D F I D W G Q G T L -

FIG. 1

2 / 6

AAGCTTTACAGTTACTCAGCACACAGGACCTCACCATGAGGTTCTCTGTTCAGTTTCTGG
1 -----+-----+-----+-----+-----+-----+ 60
TTCGAAATGTCAATGAGTCGTGTGTCTCTGGAGTGGTACTCCAAGAGACAAGTCAAAGACC
C A L Q L L S T Q D L T M R F S V Q F L G -
GGGTGCTTATGTTCTGGATCTCTGGAGTCAGTGGGGATATTGTGATAACCCAGGATGAAC
61 -----+-----+-----+-----+-----+-----+ 120
CCCACGAATACAAGACCTAGAGACCTCAGTCACCCCTATAACACTATTGGGTCCTACTTG
C V L M F W I S G V S G D I V I T Q D E L -
TCTCCAATCCTGTCACTTCTGGAGAATCAGTTTCCATCTCCTGCAGGTCTAGTAAGAGTC
121 -----+-----+-----+-----+-----+-----+ 180
AGAGGTTAGGACAGTGAAGACCTCTTAGTCAAAGGTAGAGGACGTCCAGATCATTCTCAG
C S N P V T S G E S V S I S C R S S K S L -
TCCTGTATAAGGATGGGAAGACATACTTGAATTGGTTTCTGCAGAGACCAGGACAATCTC
181 -----+-----+-----+-----+-----+-----+ 240
AGGACATATTCCTACCCTTCTGTATGAACTTAACCAAAGACGTCTCTGGTCCTGTTAGAG
C L Y K D G K T Y L N W F L Q R P G Q S P -
CTCAGCTCCTGATGTATTTGATGTCCACCCGTGCATCAGGAGTCTCAGACCGGTTTAGTG
241 -----+-----+-----+-----+-----+-----+ 300
GAGTCGAGGACTACATAAACTACAGGTGGGCACGTAGTCCTCAGAGTCTGGCCAAATCAC
C Q L L M Y L M S T R A S G V S D R F S G -
GCAGTGGGTCAGGCACAGATTTACCCTGGAAATCAGTAGAGTGAAGGCTGAGGATGTGG
301 -----+-----+-----+-----+-----+-----+ 360
CGTCACCCAGTCCGTGTCTAAAGTGGGACCTTTAGTCATCTCACTTCCGACTCCTACACC
C S G S G T D F T L E I S R V K A E D V G -
GTGTGTATTACTGTCAACAACCTTGTAGAGTATCCATTCACGTTCTGGGCTCGGGGACAAAGT
361 -----+-----+-----+-----+-----+-----+ 420
CACACATAATGACAGTTGTTGAACATCTCATAGGTAAGTGCAAGCCGAGCCCCTGTTTCA
C V Y Y C Q Q L V E Y P F T F G S G T K L -
TGGAAATAAAACGTACG
421 ----- 437
ACCTTTATTTTGCATGC
C E I K R T -

FIG. 2

3/6

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCC
1 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
CTATAACACTACTGAGTCAGAGGTGAGAGGGACGGGCAGTGGGGACCTCTCGGCCGGAGG

FRI
A [D I V M T Q S P L S L P V T P G E P A S -
69 70 117 118
ATCTCCTGTCGCTCGAGTAAGAGTCTCCTGTATAAGGATGGGAAGACATACTTGAATTGG
61 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
TAGAGGACAGCGAGCTCATTCTCAGAGGACATATTCCTACCCTTCTGTATGAACCTTAACC

CDRI
A I S C [R S S K S L L Y K D G K T Y L N] [W -
162 163
TACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTGATGTCCACCCGGGCA
121 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
ATGGACGTCTTCGGTCCCGTCAGAGGTGTGAGGACTAGATAAAGTACAGGTGGGCCCGT

FR2 CDR2
A Y L Q K P G Q S P Q L L I Y [L M S T R A -
183 184
TCAGGGGTCCCTGACAGGTTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATC
181 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 240
AGTCCCCAGGGACTGTCCAAGTCACCGTCACCTAGTCCGTGTCTAAAATGTGACTTTTAG

FR3
A S [G V P D R F S G S G S G T D F T L K I -
279 280
AGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGTCAACAGCTGGTAGAGTATCCA
241 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 300
TCGTCTCACCTCCGACTCCTACAACCCCAAATAATGACAGTTGTGACCATCTCATAGGT

CDR3
A S R V E A E D V G V Y Y C [Q Q L V E Y P -
306 307 339 340
TTCACGTTTCGGCCAAGGGACCAAGGTGGAGATCAAACGTACGGTGGCT
301 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 348
AAGTGCAAGCCGGTTCCTGGTTCCACCTCTAGTTTGCAATGCCACCGA

FR4
A F T [F G Q G T K V E I K R] T V A -

FIG. 3

1 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCCGGGGCTCCCTTAGACTC 60
CTCCACGTCGACCACCTCAGACCCCTCCGAACCATTTCTGGGCCCCCAGGGAATCTGAG
FR1
A [E V Q L V E S G G G L V K P G G S L R L -
90 91 105 106
61 TCCTGTGCAGCTAGCGGATTCACTTTTCAGTGGCTACTGGATGTCCTGGGTCGCCAGGCT
AGGACACGTCGATCGCCTAAGTGAAGTCA CCGATGACCTACAGGACCCAGGCGGTCCGA 120
CDR1
A S C A A S G F T F S [G Y W M S] [W V R Q A -
147 148
121 CCAGGGAAGGGGCTCGAGTGGGTGTCTGAAATTAGATTGAAATCTGATAATTATGCAACA
GGTCCCTTCCCCGAGCTCACCCACGACCTTAACTCTAACTTTAGACTATTAATACGTTGT 180
FR2 CDR2
A P G K G L E W V A [E I R L K S D N Y A T -
204 205
181 CATTATGCGGAGTCTGTGAAGGGGAAATTCACCATCTCAAGAGATGATTCAAAATCTAGA
GTAATACGCCTCAGACACTTCCCCTTTAAGTGGTAGAGTTCTCTACTAAGTTTATAGATCT 240
A H Y A E S V K G [K F T I S R D D S K S R -
241 CTGTATCTGCAAATGAACAGCCTGAAAACCGAGGACACGCCGTGTATTACTGTACAGAT
GACATAGACGTTTACTTGTCTGGACTTTTGGCTCCTGTGTGCGGCACATAATGACATGTCTA 300
FR3
A L Y L Q M N S L K T E D T A V Y Y C T D] -
300 301 309 310 333
301 TTCATAGACTGGGGCCAGGGAACACTAGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCA
AAGTATCTGACCCCGGTCCCTTGTGATCAGTGGCAGAGGAGTCGGAGGTGGTTCCCGGGT 360
CDR3 FR4 CONSTANT REGION
A [F I D] [W G Q G T L V T] [V S S A S T K G P -
361 TCGGTCTTCCCCCTGGCACCTCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGC
AGCCAGAAGGGGGACCGTGGGAGGAGTTCTCGTGGAGACCCCGTGTGCGCGGGACCCG 420
A S V F P L A P S S K S T S G G T A A L G -
421 TGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTG
ACGGACCAGTTCTCTGATGAAGGGGCTTGGCCACTGCCACAGCACCTTGAGTCCGCGGGAC 480
A C L V K D Y F P E P V T V S W N S G A L -
481 ACCAGCGGCGTGCACACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGC
TGGTGCGCGCACGTGTGGAAGGGCCGACAGGATGTCTAGGAGTCTGAGATGAGGGAGTCTG 540
A T S G V H T F P A V L Q S S G L Y S L S -
541 AGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAAT
TCGCACCACTGGCACGGGAGGTCTGCGAACCCTGGGTCTGGATGTAGACGTTGCACTTA 600
A S V V T V P S S S L G T Q T Y I C N V N -
601 CACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTGGAGCCCCAAATCTTGTGACAAAAC
GTGTTTCGGGTGCTTGTGGTTCACCTGTTCTTTCACCTCGGGTTTAGAACACTGTTTGA 660
A H K P S N T K V D K K V E P K S C D K T -
661 CACACATGCCCCCGTGCCAGCACCTGAACTCGCGGGGGCACCGTCAGTCTTCTCTCTC 720

5/6

GTGTGTACGGGTGGCACGGGTCGTGGACTTGAGCGCCCCCGTGGCAGTCAGAAGGAGAAG

A H T C P P C P A P E L A G A P S V F L F -

721 CCCCCAAAACCAAGGACACCCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTG
-----+-----+-----+-----+-----+ 780
GGGGGTTTTGGGTTCTGTGGGAGTACTAGAGGGCCTGGGGACTCCAGTGACGCACCAC

A P P K P K D T L M I S R T P E V T C V V -

781 GTGGACGTGAGCCACGAAGACCCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAG
-----+-----+-----+-----+-----+ 840
CACCTGCACCTCGGTGCTTCTGGGACTCCAGTTCAAGTTGACCATGCACCTGCCGCACCTC

A V D V S H E D P E V K F N W Y V D G V E -

841 GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTG
-----+-----+-----+-----+-----+ 900
CACGTATTACGTTCTGTTTCGGCGCCCTCCTCGTCATGTTGTCTGTCATGGCACACCAG

A V H N A K T K P R E E Q Y N S T Y R V V -

901 AGCGTCCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTC
-----+-----+-----+-----+-----+ 960
TCGCAGGAGTGGCAGGACGTGGTCTGACCGACTTACCGTTCCTCATGTTACGTTCCAG

A S V L T V L H Q D W L N G K E Y K C K V -

961 TCCAACAAAGCCCTCCCAGCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCC
-----+-----+-----+-----+-----+ 1020
AGGTTGTTTCGGGAGGGTCGGGGTAGCTCTTTGGTAGAGGTTTCGGTTTCCCGTCGGG

A S N K A L P A P I E K T I S K A K G Q P -

1021 CGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTC
-----+-----+-----+-----+-----+ 1080
GCTCTTGGTGTCCACATGTGGGACGGGGTAGGGCCCTACTCGACTGGTCTTGGTCCAG

A R E P Q V Y T L P P S R D E L T K N Q V -

1081 AGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGC
-----+-----+-----+-----+-----+ 1140
TCGGACTGGACGGACCAGTTTCCGAAGATAGGGTCGCTGTAGCGGCACCTCACCTCTCG

A S L T C L V K G F Y P S D I A V E W E S -

1141 AATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC
-----+-----+-----+-----+-----+ 1200
TTACCCGTCGGCCTCTTGTGATGTTCTGGTGGGAGGGCACGACCTGAGGCTGCCGAGG

A N G Q P E N N Y K T T P P V L D S D G S -

1201 TTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTC
-----+-----+-----+-----+-----+ 1260
AAGAAGGAGATGTCGTTGAGTGGCACCTGTTCTCGTCCACCGTCGTCCCCTTGCAGAAG

A F F L Y S K L T V D K S R W Q Q G N V F -

1261 TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTG
-----+-----+-----+-----+-----+ 1320
AGTACGAGGCACTACGTACTCCGAGACGTGTTGGTGATGTGCGTCTTCTCGGAGAGGGAC

A S C S V M H E A L H N H Y T Q K S L S L -

1321 TCTCCGGGTAAATGA
-----+----- 1335
AGAGGCCCATTTACT


A S P G K * -

FIG. 4 CONT'D

6 / 6

$$y=(A-D)/(1+(x/C)^B)+D$$

$$A=0.0501 \quad B=1.31 \quad C=60.3 \quad D=3.74$$




CHIMERIC CD23 IgG1m
HALF MAXIMUM BINDING=16.28ng/ml

FIG. 5

$$y=(A-D)/(1+(x/C)^B)+D$$

$$A=0.104 \quad B=1.49 \quad C=37.7 \quad D=3.78$$



HUMANIZED CD23 IgG1m
HALF MAXIMUM BINDING=15.03ng/ml

FIG. 6

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY'S
DOCKET NUMBER

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Antibodies to CD23, Derivatives Thereof, and Their Therapeutic Uses

the specification of which (check only one item below):

☐ is attached hereto

☐ was filed as United States application Serial No _____ on _____ and was amended on _____ (if applicable).

☒ was filed as PCT international application Number PCT.GB99.01434 on 07-May-1999

and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 and all information which became available between the filing of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign applications(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
1. United Kingdom	9809839.5	09-May-1998	
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No..	Filing Date (MM/DD/YYYY)
1.	
2.	
3.	
4.	
5.	

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Continued – Includes References to PCT International Applications)				ATTORNEY'S DOCKET NUMBER	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. FILING NUMBERS ASSIGNED (if any)			
PCT.GB99.01434	07-May-1999		X		
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardise the validity of the application or any patent issued thereon.</p>					
<p>I hereby appoint <u>NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000</u> (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, <u>25327</u>; Larry S. Nixon, <u>25640</u>; Robert A. Vanderhye, <u>27076</u>; James T. Hosmer, <u>30184</u>; Robert W. Faris, <u>31352</u>; Richard G. Besha, <u>22770</u>; Mark E. Nusbaum, <u>32348</u>; Michael J. Keenan, <u>32106</u>; Bryan H. Davidson, <u>30251</u>; Stanley C. Spooner, <u>27393</u>; Leonard C. Mitchard, <u>29009</u>; Duane M. Byers, <u>33363</u>; Jeffrey H. Nelson, <u>30481</u>; John R. Lastova, <u>33149</u>; H. Warren Burnam, Jr., <u>29366</u>; Thomas E. Byrne, <u>32205</u>; Mary J. Wilson, <u>32955</u>; J. Scott Davidson, <u>33489</u>; Alan M. Kagen, <u>36178</u>; William J. Griffin, <u>31260</u>; Robert A. Molan, <u>29834</u>; B. J. Sadoff, <u>36663</u>; James D. Berquist, <u>34776</u>; Updeep S. Gill, <u>37334</u>.</p>					
<p>Send Correspondence to: <u>Nixon & Vanderhye PC</u> <u>8th Floor,</u> <u>1100 North Glebe Road</u> <u>Arlington</u> <u>Virginia 22201-4714</u> <u>USA</u> <u>ixon & Vanderhye PC</u> <u>8th Floor, 1100 North Glebe Road</u> <u>Arlington, VA 22201-4714</u></p>			<p>Direct Telephone Calls to:</p>		

1-00 Inventor's signature [Signature] Date 23/11/00
 Inventor's Name (typed) Jean-Yves Marcel Paul BONNEFOY Nationality: French
 First Middle Initial Family Name Citizenship
 Residence (City) Le Sappey FR (State/Foreign Country) FRANCE
 Post Office Address Institute de Recherche Pierre Fabre, 74164 Saint-Julien-en-Genevois,
Cedex, France

2. Inventor's signature _____ Date _____
 Inventor's Name (typed) James Scott CROWE Nationality: British
 First Middle Initial Family Name Citizenship
 Residence (City) _____ (State/Foreign Country) _____
 Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

3. Inventor's signature _____ Date _____
Inventor's Name (typed) Jonathan Henry ELLIS Nationality:
British
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

4. Inventor's signature _____ Date _____
Inventor's Name (typed) Nicholas Timothy RAPSON Nationality:
British
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

5. Inventor's signature _____ Date _____
Inventor's Name (typed) Jean SHEARIN Nationality:
American
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address Glaxo Wellcome Inc.,, Five Moore Drive, Research Triangle Park, North
Carolina 27709, USA

6. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

7. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

8. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY'S
DOCKET NUMBER

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Antibodies to CD23, Derivatives Thereof, and Their Therapeutic Uses

the specification of which (check only one item below):

☐ is attached hereto

☐ was filed as United States application Serial No _____ on _____ and was amended on _____ (if applicable).

☒ was filed as PCT international application Number PCT.GB99.01434 on 07-May-1999 ✓

and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 and all information which became available between the filing of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
1. United Kingdom ✓	9809839.5 ✓	09-May-1998 ✓	
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No..	Filing Date (MM/DD/YYYY)	
1.		
2.		
3.		
4.		
5.		

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Continued – Includes References to PCT International Applications)				ATTORNEY'S DOCKET NUMBER	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. FILING NUMBERS ASSIGNED (if any)			
PCT. GB99.01434	07-May-1999			X	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardise the validity of the application or any patent issued thereon.</p>					
<p>I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334.</p>					
Send Correspondence to: <u>Nixon & Vanderhye PC</u> <u>8th Floor</u> <u>1100 North Glebe Road</u> <u>Arlington</u> <u>Virginia 22201-4714</u> USA Nixon & Vanderhye PC 8th Floor, 1100 North Glebe Road Arlington, VA 22201-4714				Direct Telephone Calls to:	

1. Inventor's signature _____ Date _____
 Inventor's Name (typed) Jean-Yves Marcel Paul BONNEFOY Nationality: French

First Middle Initial Family Name Citizenship

Residence (City) _____ (State/Foreign Country) _____
 Post Office Address Institute de Recherche Pierre Fabre, 74164 Saint-Julien-en-Genevois,
Cedex, France

2-50 Inventor's signature X James Scott Crowe Date X 21st November 2000
 Inventor's Name (typed) James Scott CROWE Nationality: British

First Middle Initial Family Name Citizenship

Residence (City) X (State/Foreign Country) X
 Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom GBX

3. Inventor's signature [Signature] Date 27/11/88
Inventor's Name (typed) Jonathan Henry ELLIS Nationality: British
First Middle Initial Family Name Citizenship ✓
Residence (City) X WARE GBX (State/Foreign Country) X UK
Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

4. Inventor's signature N. T. Rapson Date 28/11/00
 +00 Inventor's Name (typed) Nicholas Timothy RAPSON Nationality: British
 First Middle Initial Family Name Citizenship ✓
 Residence (City) X Cambridge GBX (State/Foreign Country) X UK
 Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

5.	Inventor's signature			Date
	Inventor's Name (typed)	Jean	SHEARIN	Nationality:
				American
	First	Middle Initial	Family Name	Citizenship
	Residence (City) (State/Foreign Country)			
	Post Office Address Glaxo Wellcome Inc.,, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA			

6. Inventor's signature _____ Date _____
Inventor's Name (typed) _____

First	Middle Initial	Family Name	Citizenship
Residence (City) _____ (State/Foreign Country) _____			
Post Office Address _____			

7. Inventor's signature _____ Date _____
Inventor's Name (typed) _____

First	Middle Initial	Family Name	Citizenship
Residence (City) _____ (State/Foreign Country) _____			
Post Office Address _____			

8. Inventor's signature _____ Date _____
Inventor's Name (typed) _____
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY'S
DOCKET NUMBER

As below named inventor. I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Antibodies to CD23, Derivatives Thereof, and Their Therapeutic Uses

the specification of which (check only one item below):

☐ is attached hereto

☐ was filed as United States application Serial No _____ on _____ and was amended on _____ (if applicable).

☒ was filed as PCT international application Number PCT.GB99.01434 on 07-May-1999 ✓

and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 and all information which became available between the filing of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
1. United Kingdom ✓	9809839.5 ✓	09-May-1998 ✓	
2.			
3.			
4.			
5.			

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:


Application No..	Filing Date (MM/DD/YYYY)	
1.		
2.		
3.		
4.		
5.		

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Continued – Includes References to PCT International Applications)				ATTORNEY'S DOCKET NUMBER	
<p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:</p>					
PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:					
U.S. APPLICATIONS			STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. FILING NUMBERS ASSIGNED (if any)			
PCT.GB99.01434	07-May-1999			X	
<p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true, and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardise the validity of the application or any patent issued thereon.</p>					
<p>I hereby appoint <u>NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000</u> (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; William J. Griffin, 31260; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334.</p>					
Send Correspondence to: <u>Nixon & Vanderhye PC</u> <u>8th Floor</u> <u>1100 North Glebe Road</u> <u>Arlington</u> <u>Virginia 22201-4714</u> USA Nixon & Vanderhye PC 8 th Floor, 1100 North Glebe Road Arlington, VA 22201-4714				Direct Telephone Calls to:	

1. Inventor's signature _____ Date _____
 Inventor's Name (typed) Jean-Yves Marcel Paul BONNEFOY Nationality: French
- First Middle Initial Family Name Citizenship
- Residence (City) _____ (State/Foreign Country) _____
 Post Office Address Institute de Recherche Pierre Fabre, 74164 Saint-Julien-en-Genevois,
Cedex, France
2. Inventor's signature _____ Date _____
 Inventor's Name (typed) James Scott CROWE Nationality: British
- First Middle Initial Family Name Citizenship
- Residence (City) _____ (State/Foreign Country) _____
 Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY,
United Kingdom

3. Inventor's signature _____ Date _____
Inventor's Name (typed) Jonathan Henry ELLIS Nationality: British
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom

4. Inventor's signature _____ Date _____
Inventor's Name (typed) Nicholas Timothy RAPSON Nationality: British
First Middle Initial Family Name Citizenship
Residence (City) _____ (State/Foreign Country) _____
Post Office Address Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom

5. Inventor's signature  Date 11/27/00
5-00 Inventor's Name (typed) Jean SHEARIN Nationality: American
First Middle Initial Family Name Citizenship ☒

Residence (City) Durham, NC (State/Foreign Country) North Carolina
Post Office Address Glaxo Wellcome, Inc., Five Moore Drive, Research Triangle Park, North Carolina 27709, USA

6. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship

Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

7. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship

Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____

8. Inventor's signature _____ Date _____
Inventor's Name (typed) First Middle Initial Family Name Citizenship

Residence (City) _____ (State/Foreign Country) _____
Post Office Address _____